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Tiivistelmä  Referat Abstract 
Active transport processes in the basolateral (sinusoidal) membrane of hepatocytes have an 
important role in the hepatic clearance and overall disposition for several types of drugs. 
Organic anion transporting polypeptides (OATPs) expressed in the sinusoidal membrane 
have been shown to mediate the sodium-independent hepatic uptake of broad range of drugs 
and they have been associated with clinically relevant drug-drug interactions (DDIs) and 
genetic polymorphisms. The literature review focuses on sinusoidal OATP transporters and 
on the pharmacokinetic effects of OATP-mediated hepatic uptake. In addition, current 
methods to investigate the interactions between drugs and transporters are discussed, with 
the emphasis on methods applicable to study uptake transporters. 
 
The aim of the experimental part of the master’s thesis was to determine if two clinically used 
drugs, entacapone and fluvastatin, are actively transported from blood into rat and human 
hepatocytes, and to assess the role of OATP transporters in the hepatic uptake of the drugs 
in comparison with known OATP substrates, estrone 3-sulfate (E3S) and taurocholic acid and 
broad OATP inhibitor rifamycin SV. The uptake kinetics of compounds of interest were 
determined in freshly isolated and cryopreserved rat hepatocytes and in cryopreserved 
human hepatocytes using the oil-spin method. Uptake clearances (CLuptake) via active uptake 
(CLactive) and passive diffusion (Pdiff) were calculated from the initial uptake data over a 1 - 200 
µM and 1 - 50 µM concentration range for entacapone and fluvastatin, respectively. The half-
maximal inhibitor concentration (IC50) of E3S uptake transport was determined for 
entacapone in a competitive uptake experiment over a 10 – 400 µM concentration range. 
 
Fluvastatin uptake showed active saturable transport kinetics in rat hepatocytes with a Km 
value of 6 µM, whereas entacapone uptake in rat hepatocytes was somewhat linear and did 
not inhibit E3S uptake at clinically significant concentrations, with an IC50 value of 240 µM. 
Significantly lower hepatic uptake of taurocholate and entacapone was observed between rat 
and human hepatocytes, indicating species differences in hepatic uptake processes, although 
cryopreservation may have had an effect on the noticed difference.  The results suggest that 
murine Oatp transporters do not have a significant contribution to hepatic uptake of 
entacapone. However, this should be confirmed with future studies with more repetitions and 
a reliable quantification method.  
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Tiivistelmä ReferatAbstract 
Maksasolujen basolateraalisen (sinusoidaalisen) solukalvon aktiivisilla kuljetusmekanismeilla 
on suuri vaikutus monien lääkeaineiden maksapuhdistumaan sekä laajemmin 
farmakokineettisiin jakautumis- ja eliminaatiovaiheisiin. Sinusoidaalikalvolla ilmentyvien 
orgaanisia anioneita kuljettavien polypeptidien (engl. organic anion transporting polypeptides, 
OATP) on huomattu kuljettavan maksasoluihin laajasti erityyppisiä lääkeaineita. Monien 
kliinisesti merkittävien lääke-lääkeyhteisvaikutusten on havaittu liittyvän OATP-
kuljetinproteiinien estyneeseen tai rajoittuneeseen toimintaan. Samoin useat geneettiset 
polymorfismit vaikuttavat OATP-substraattien farmakokinetiikkaan, tehoon ja toksisuuteen. 
Kirjallisuuskatsauksessa tarkastellaan sinusoidaalisten OATP-kuljetinproteiinien vaikutusta 
lääkkeiden farmakokinetiikkaan sekä tarjolla olevia menetelmiä kuljetinproteiinien tutkimiseen 
lääkekehityksessä.  
 
Erikoistyön tavoitteena oli selvittää, onko fluvastatiinin ja entakaponin soluunotto aktiivista 
rotan ja ihmisen maksasoluissa, sekä arvioida OATP-kuljetinproteiinien merkitystä näiden 
lääkkeiden maksasoluunotossa. Lääkeaineiden soluunottokinetiikkaa tutkittiin tuoreissa 
eristetyissä rotan maksasoluissa sekä pakastetuissa rotan ja ihmisen maksasoluissa käyttäen 
öljyn läpi -sentrifugointimenetelmää. Soluunoton alkunopeus määritettiin entakaponi-
pitoisuuksilla 1 -200 µM ja fluvastatiinipitoisuuksilla 1 - 50 µM. Määritetyistä arvoista arvioitiin 
aktiivisen (CLactive) ja passiivisen (Pdiff) mekanismin osuudet lääkeaineiden soluunotossa. 
Lisäksi rotan Oatp-kuljetinproteiinien merkitystä entakaponin soluunottoon tutkittiin 
pitoisuusalueella 10- 400 µM kilpailevassa soluunottokokeessa Oatp-substraatti estroni-3-
sulfaatin kanssa. 
 
Fluvastatiinin soluunotto rotan maksasoluihin oli saturoituvaa, ja laskennallinen Km-arvo oli 6  
µM. Sitä vastoin entakaponin soluunotto oli lineaarista tutkitulla pitoisuusalueella, eikä estroni-
3-sulfaatin soluunotto estynyt kliinisesti merkittävillä entakaponipitoisuuksilla IC50-arvon 
(puolet maksimaalisesta inhibitiopitoisuudesta) ollessa 240 µM. Entakaponin soluunotto oli 
huomattavasti alhaisempaa ja hitaampaa ihmisen maksasoluissa verrattuna rotan 
maksasoluihin, mikä viittaa lajien välisiin eroihin soluuottomekanismeissa. Havainto voi 
kuitenkin selittyä tuoreiden ja pakastettujen solujen välisillä eroilla. Kokonaisuudessaan 
tulokset viittaavat siihen, että entakaponi ei ole fluvastatiinin tavoin rotan Oatp-
kuljetinproteiinien substraatti. Tulosten luotettavuus tulisi kuitenkin vahvistaa uusissa kokeissa 
käyttäen rinnakkaisia määrityksiä ja luotettavaa menetelmää näytteiden 
lääkeainepitoisuuksien määrittämiseksi. 
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1 INTRODUCTION 
 
Cell membrane transporters have a significant role in drug elimination by the liver. For 
several types of drugs, the active transport of the compound through the basolateral 
membrane of hepatocytes has been demonstrated to be not only an important 
determinant of the hepatic clearance of drugs but also the rate-limiting step for drug 
disposition as a whole (Simonson et al. 2004; Shitara et al. 2006; Maeda et al. 2011). 
Consequently, the inhibition or induction of hepatic transporters may cause a notable 
change in drug concentration in the liver and plasma and result in inefficacy or 
increased toxicity. Also drug-drug interactions and inter-individual variability in the 
expression and functionality of hepatic transporters may similarly affect safety and 
efficacy of drugs. 
 
Given the importance of transporters on pharmacokinetics, efficacy and toxicity of 
drugs, there has been a lot of interest in developing effective models for evaluating 
drug-transporter interactions. Characterization of a compound as a transporter substrate 
or inhibitor early in the drug development process aids in the selection of dosing 
regimen and may lead to the design and conduct of drug-drug interaction studies, or 
evaluation of the outcomes of possible genetic polymorphisms (Giacomini et al. 2010).  
 
The objective of the literature review of this master’s thesis is to consider the 
pharmacokinetic effects of active transport on the basolateral membrane of hepatocytes, 
and to provide an overview of the available methods of studying drug-transporter 
interactions. The focus is on hepatic organic anion transporting polypeptide (OATP) 
transporters OATP1B1 and -1B3 which have shown to be involved in the hepatic uptake 
of an increasing number of clinically used drugs. 
 
The hepatic uptake two drugs, fluvastatin and entacapone, is further examined in the 
experimental part. Hepatic uptake is a prerequisite for the pharmacologic effect of 
antihyperlipidemic HMG-CoA reductase inhibitors such as fluvastatin and the main 
route of elimination for most of statins including fluvastatin is via the bile after 
metabolism by the liver (Dansette et al. 2000; Schachter 2005). Thus, inhibition or 
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altered activity of active hepatic uptake of statins may be a major mechanism of reduced 
efficacy and toxic effects such as myopathy. Similar to fluvastatin, catechol O-
methyltransferase (COMT) inhibitor entacapone used in the treatment of Parkinson’s 
disease is considered a high clearance drug with significant first-pass metabolism and it 
appears to be eliminated mainly via biliary excretion (Wikberg et al. 1993; Heikkinen et 
al. 2001). OATPs have been identified to have a significant contribution for hepatic 
uptake of fluvastatin (Noe et al. 2007; Greupink et al. 2011). However, no published 
data about hepatic transport mechanisms of entacapone are available and role of hepatic 
uptake transporters on entacapone pharmacokinetics is unclear. In the present study, the 
role of OATPs in the sinusoidal uptake of entacapone is evaluated in comparison with 
fluvastatin and known substrates of OATP-mediated transport. 
 
 
2 ACTIVE TRANSPORT IN THE LIVER 
 
2.1 Liver Function and Drug Metabolism 
 
The liver is responsible for the majority of drug metabolism in the body due to a very 
high concentration of most of the drug metabolizing enzymes and a unique blood supply 
from the digestive organs (Murray et al. 1988; de Waziers et al. 1990; Lakehal et al. 
1999). Majority of the blood leaving the digestive system passes through the hepatic 
portal vein and is then delivered to the liver parenchyma where the contents of the blood 
are processed before being passed on to other parts of the body (Vollmar and Menger 
2009). The functions of the liver include metabolism, storage and synthesis of glucose 
and lipids, synthesis and degradation of proteins and glycoproteins, as well as 
metabolism and degradation of several hormones and xenobiotics, such as drugs 
(Jungermann and Kietzmann 1996). Accordingly, the essential role of the liver is to 
regulate the entry of nutrients and xenobiotics into the body.  
 
The purpose of hepatic drug metabolism is to facilitate the excretion of drugs in urine or 
bile by chemical modification to more water soluble forms. Hepatic metabolism process 
can be divided into three phases, where phase I consists of mainly oxidation, reduction 
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and hydrolysis reactions catalyzed by cytochrome P450 enzymes (CYPs), followed by 
further enzymatic conjugation reactions with charged species such as glutathione, 
sulfate, glycine, or glucuronic acid in phase II, and finally excretion of metabolites out 
of the cells in phase III (Ishikawa 1992; Roberts et al. 2002; Nakata et al. 2006). 
 
2.2 Structure of the Liver Parenchyma 
 
The liver is formed by parenchymal cells, i.e. hepatocytes, and nonparenchymal cells, 
including sinusoidal endothelial cells, phagocytic Kupffer cells, hepatic stellate cells, 
and intrahepatic lymphocytes (Ishibashi et al. 2009). Hepatocytes constitute almost 80 % 
of the total volume of the liver and perform the majority of the organ’s metabolic 
functions (Blouin et al. 1977; Ishibashi et al. 2009). The parenchyma is composed of 
structural units referred to as lobules, roughly hexagonal prisms with portal tracts - each 
with a portal venule, a hepatic arteriole and a bile duct - at each of the corners (Figure 1) 
(Ishibashi et al. 2009). Blood from the portal tracts flows through small sinusoids lining 
single layers of hepatocytes, and into the central vein that forms the hub of the lobule. 
Bile flows the opposite way from small bile canaliculi running between hepatocytes to 
the interlobular bile ducts of the portal tracts. Each layer of hepatocytes is thus 
separated by either a sinusoid or a bile canaliculus. The interconnecting layers of 
hepatocytes radiate from the central vein to the periphery forming the six-sided shape of 
the lobule.  
 
Hepatic elimination process involves the uptake of xenobiotics from the sinusoidal 
blood into hepatocytes where enzymatic metabolism occurs, followed by excretion 
either into bile or back into sinusoidal blood with subsequent elimination by other 
organs, such as kidney (Kusuhara and Sugiyama 2010). The specialized structure of 
hepatocytes enables the flux of substrates through the hepatobiliary system. Hepatocytes 
are highly polarized epithelial cells with three distinct membrane domains (Hubbard et 
al. 1983). The basal domain, characterized by irregular microvilli, is a large surface 
facing the space between porous sinusoidal endothelial cells and hepatocytes, known as 
the space of Disse or perisinusoidal space (Hubbard et al. 1983; Jungermann and 
Kietzmann 1996).  
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Figure 1. Lobular structure of the liver. The hepatocytes in a liver lobule form a series 
of irregular plates arranged in hexagonal prisms. (Martini and Nath 2011).  
 
 
Also called the sinusoidal membrane, the basal surface is specialized for exchange of 
solutes with plasma in the perisinusoidal space.  The lateral domain is a smooth surface 
contiguous to a neighboring lateral membrane and it bears several types of junctional 
elements, such as tight junctions, desmosomes, and gap junctions (Hubbard et al. 1983). 
Separated from the lateral membrane by tight junctions, the apical membrane is a small 
microvillous area known as canalicular membrane. The canalicular membrane is 
specialized for bile secretion into bile canaliculi via numerous efflux transporters. The 
canalicular membranes of adjacent hepatocytes form the walls of the bile canaculi. 
 
 
2.3 Hepatocyte Membrane Transporters 
 
The highly fenestrated membrane of sinusoidal endothelial cells allows passage of 
substances carried in the blood into the perisinusoidal space, from where they can be 
taken up into hepatocytes through the sinusoidal membrane (Fraser et al. 1978; Braet 
and Wisse 2002; Geraud et al. 2012). Small lipophilic molecules may pass the 
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membrane by simple or facilitated diffusion (FDA 2000). However, the exchange of 
some lipophilic and various amphipathic and polar substances is actively facilitated 
against electrochemical potential gradient by several membrane bound transport 
proteins. The majority of basolateral uptake transporters belong to the gene superfamily 
of solute carriers (SLC), including the Na
+
-taurocholate co-transporting polypeptide 
(NTCP), organic anion transporting polypeptides (OATPs), and organic anion and 
cation transporters (OATs, OCTs) (Figure 2) (Faber et al. 2003; Chandra and Brouwer 
2004).  
 
 
Figure 2. Membrane transporters in human hepatocytes. Basolateral influx transporters 
(black) transport drugs from sinusoidal blood into hepatocytes where they are 
metabolized. Efflux transporters (grey) pump the metabolites either into bile or back 
into blood (Fahrmayr et al. 2010).  
 
Efflux transporters belonging to the adenosine triphosphate (ATP) binding cassette 
(ABC) superfamily are mainly expressed on the canalicular membrane, including ABCB 
family members P-glycoprotein (P-gp), and bile salt export pump (BSEP), the ABCC 
family member multidrug resistance associated protein 2 (MRP2), and the ABCG family 
member breast cancer resistant protein (BCRP) (Figure 2) (Faber et al. 2003; Chandra 
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and Brouwer 2004). Also multidrug and toxin extrusion transporter (MATE1), a non-
ABC transporter that uses the proton gradient as a driving force, has been identified in 
the canalicular membrane (Otsuka et al. 2005). A variety of MRPs and a non-ABC 
transporter, heteromeric organic solute transporter (OST) OSTα-OSTβ, are also 
expressed in the basolateral membrane pumping metabolites back into sinusoidal blood 
(Faber et al. 2003; Ballatori et al. 2005). Consequently, the substrate specificity of 
efflux pumps in the canalicular and basolateral membrane direct the way drug 
metabolites are excreted, i.e. via the bile or via the urine.  
 
2.4 Organic Anion Transporting Polypeptides 
 
Human organic anion transporting polypeptides (OATPs) are 12 transmembrane domain 
proteins that mediate the sodium-independent uptake of a wide range of amphipathic 
organic compounds (Kullak-Ublick et al. 1995; Tamai et al. 2000; Adachi et al. 2003). 
OATPs belong to the gene superfamily SLCO (formerly SLC21) which is subdivided 
into 6 families (OATP1-OATP6) and 13 subfamilies (Hagenbuch and Meier 2004). 
Their transport mechanism has not yet been fully elucidated. The suggested mechanism 
is anion exchange, in which the uptake of organic anions is coupled with the efflux of 
neutralizing anions such as bicarbonate and glutathione (Satlin et al. 1997; Li et al. 
2000). OATP-mediated transport appears to be pH-dependent but independent of 
sodium, chloride and potassium gradients, membrane potential and ATP levels (Kullak-
Ublick et al. 1995; Kobayashi et al. 2003; Mahagita et al. 2007). Most OATPs have a 
wide substrate spectrum and tissue distribution, including brain, kidney, testis, intestine 
and liver (Hagenbuch and Meier 2004). However, the OATP1 subfamily members 
OATP1B1 and OATP1B3 are localized exclusively in the basolateral membrane of 
hepatocytes, except for tumor tissues (König et al. 2000a; König et al. 2000b). The third 
OATP family member expressed in the sinusoidal membrane is OATP2B1, which is 
also expressed in other tissues such as intestine, placenta and ciliary body (Kullak-
Ublick et al. 2001; St-Pierre et al. 2002; Kraft et al. 2010). Also OATP1A2 is expressed 
in the liver among other tissues but the liver expression is localized specifically to 
epithelial cells of the bile duct instead of hepatocytes (Lee et al. 2005). 
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OATP1B1 and OATP1B3 share overlapping substrate specificity and are capable of 
transporting a large variety of endogenous compounds, including bile salts such as 
taurocholate, steroid hormones and their conjugates such as estrone-3-sulfate, as well as 
thyroid hormones and bilirubin (Tamai et al. 2000; König et al. 2000b; Kullak-Ublick et 
al. 2001; Cui et al. 2001). In addition, numerous drugs have been identified as their 
substrates, including antihyperlipidemic drugs (ezetimibe, pravastatin, rosuvastatin, 
pitavastatin, fluvastatin), anti-histamines (fexofenadine), anticancer drugs (methotrexate) 
and antidiabetic drugs (repaglinide).  (Kopplow et al. 2005; Shimizu et al. 2005; Seithel 
et al. 2007; Niemi et al. 2011). Three HMG-CoA inhibitors, fluvastatin, atorvastatin and 
rosuvastatin, are also substrates for OATP2B1 (Kopplow et al. 2005; Grube et al. 2006). 
Also two structurally related antibiotics, rifamycin SV and rifampicin, have been shown 
to interact with OATP-mediated transport. Rifampicin mainly inhibits OATP1B3, while 
rifamycin SV is a potent inhibitor of all human liver OATPs (Vavricka et al. 2002). The 
broad and partially overlapping substrate specificity of hepatic OATP transporters 
indicates that they play an important role in hepatic elimination process of many drugs 
together with other transporters with wide substrate spectrum, such as P-glycoprotein 
and MRPs. 
 
There are species differences in the protein structure, functionality, substrate specificity 
and tissue distribution of transporters belonging to the SLCO gene superfamily. In 
rodents, 14 members of OATP/SLCO family (Oatps in rodents) have been identified, 
some of which do not exist in humans (Hagenbuch and Meier 2004). Three Oatp 
transporters, Oatp1a1, Oatp1a4 and Oatp1b2, are expressed in rat hepatocytes 
(Bergwerk et al. 1996; Reichel et al. 1999; Li et al. 2002). Direct human orthologues of 
these transporters have not been identified. Similar to OATP1A2, the tissue expression 
of Oatp1a1 and Oatp1a4 is not limited to liver but they are expressed also in other 
tissues such as kidney and brain, respectively (Li et al. 2002). They also share similar 
substrates with OATP1A2, including conjugated bile acids, sulfated steroids, β-lactam 
antibiotics and fexofenadine (Cvetkovic et al. 1999; Cattori et al. 2001). Oatp1b2 
resembles OATP1B1 and -1B3 in substrate specificity and predominant expression in 
the sinusoidal membrane (Li et al. 2002). Members of OATP/SLCO family expressed in 
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the basolateral membrane of human and rat hepatocytes are summarized in Table 1, 
together with their tissue distribution and selected drug substrates. 
 
Table 1. Summary of members of OATP/SLCO superfamily expressed in human and rat 
hepatocytes, their tissue distribution and selected substrates. Capital symbols stand for 
human genes and gene products while lower case symbols denote rodent genes and gene 
products (Kouzuki et al. 1999; Eckhardt et al. 1999; Cattori et al. 2001; Kullak-Ublick 
et al. 2001; Noe et al. 2007; Fahrmayr et al. 2010; Greupink et al. 2011; Varma et al. 
2011).  
Gene 
symbol 
Protein 
name 
Substrates/Inhibitors Tissue Distribution 
Slco1a1 Oatp1a1 
 
Estrone 3-sulfate, taurocholate, 
rifamycin SV, pravastatin 
Liver, kidney, brain 
Slco1a4 Oatp1a4 
 
Estrone 3-sulfate, taurocholate, 
rifamycin SV, rifampicin, 
atorvastatin, pitavastatin, pravastatin, 
rosuvastatin 
 
Liver, brain, ciliary 
body, retina 
SLCO1B1 OATP1B1 
 
Estrone 3-sulfate, taurocholate, 
rifamycin SV, fluvastatin, 
atorvastatin, cerivastatin, lovastatin, 
pitavastatin, pravastatin, 
rosuvastatin, simvastatin 
Liver 
Slco1b2 Oatp1b2 
 
Estrone 3-sulfate, taurocholate, 
rifampicin, fluvastatin, lovastatin, 
pravastatin  
Liver, ciliary body 
SLCO1B3 OATP1B3 
 
Estrone 3-sulfate, taurocholate, 
rifamycin SV, rifampicin, 
fluvastatin, pitavastatin, pravastatin, 
rosuvastatin 
Liver, cancer cell lines 
SLCO2B1 OATP2B1 
 
Estrone 3-sulfate, rifamycin SV,  
fluvastatin, atorvastatin, rosuvastatin 
 
Intestine, liver, 
placenta, ciliary body 
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3 PHARMACOKINETIC EFFECTS OF HEPATIC OATP TRANSPORTERS 
 
3.1 Saturable Transport and Hepatic Drug Clearance 
 
The transport capacity of the membrane transporters is limited. The transport process is 
saturable when the rate of transport ceases to increase in direct proportion to substrate 
concentration and approaches an upper limit (Rowland and Tozer 2011). Active, 
saturable transport follows Michaelis-Menten kinetics, where the rate of transport 
approaches a maximum, Vmax, by the relationship: 
 
  
      
    
  Equation 1 
 
in which Km is the Michaelis-Menten constant and S is the substrate concentration at the 
transporter binding site. At substrate concentrations well below Km, rate of transport and 
substrate concentration vary in direct proportion and the transport kinetics is linear. 
However, at concentrations above Km, the kinetics become nonlinear and show 
saturability as the transport rate approaches the value of Vmax. Nonlinearity of saturable 
transport processes in drug elimination can be problematic since it may cause unwanted 
drug accumulation with increasing doses.  
 
Cooperation of uptake and efflux transporters in transcellular transport of drugs and 
their metabolites has an essential role in the hepatic elimination process and may have a 
major impact on the systemic clearance and exposure of many drugs (Zamek-
Gliszczynski et al. 2006; Nies et al. 2008). In addition to transporter-mediated pathways, 
drug transport across the hepatic membranes occurs also by passive diffusion. The 
importance of transporters in the hepatic clearance depends on the contribution of both 
the transporter-mediated pathways and the passive processes. The permeation clearance 
of unbound drugs for influx across sinusoidal membrane is comprised of transporter-
mediated uptake clearance (PSinf,act) and passive diffusional clearance (PSdiff) (Shitara et 
al. 2013). The overall hepatic clearance (CLint,all) consists of permeation clearances of 
unbound drugs for uptake and efflux across the sinusoidal membrane (PSinf and PSeff, 
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respectively) and the intrinsic clearance for metabolism and/or biliary excretion (CLint) 
(Equation 2).  
 
         
               
                  
       Equation 2 
 
For highly permeable drugs, neither active uptake nor efflux is the rate-limiting step in 
the overall hepatic clearance (Giacomini et al. 2010). However, most anionic drugs, as 
well as some hydrophilic organic cationic and zwitterionic drugs have poor membrane 
permeability (FDA 2000). For these drugs, membrane permeation is mainly dependent 
on active processes and uptake or efflux clearances can be rate-determining in some 
cases (Giacomini et al. 2010). Active hepatic uptake becomes the rate-determining 
process of the overall hepatic clearance when sinusoidal efflux clearance is negligible 
and CLint is much larger than passive diffusional clearance (Shitara et al. 2013). 
 
3.2 Drug-Drug Interactions 
 
Due to the wide substrate specificity of OATP transporters, many simultaneously 
administered drugs compete of the same transporter binding sites causing saturation of 
transport capacity and inhibition of drug uptake. In addition, not all OATP inhibitors are 
OATP substrates but inhibit the uptake via other mechanisms. OATP-mediated drug-
drug interactions (DDIs) may be clinically significant when OATP-mediated uptake is 
the rate-determining process of the overall hepatic clearance. This has been reported to 
be the case for many statins, such as atorvastatin, pravastatin and rosuvastatin. In a 
clinical study by Maeda et al. (2011), the oral coadministration of OATP1 inhibitor 
rifampicin increased the AUC (area under the plasma concentration-time curve) of 
atorvastatin, while coadministration of CYP3A4 inhibitor itraconazole did not change 
the plasma exposure of atorvastatin, although atorvastatin is metabolized by CYP3A4. 
The effects were similar for pravastatin, which is only minimally metabolized in the 
liver. Simonson et al. (2004) have published similar results for rosuvastatin when 
coadministered with immunosupressant cyclosporine, another OATP1 inhibitor. The 
AUC and maximum plasma concentration (Cmax) values for rosuvastatin were increased 
significantly in heart transplant recipients on an antirejection regimen including 
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cyclosporine. In addition to rifampicin and cyclosporine, also antidiabetic drug 
repaglinide and macrolide antibiotics clarithromycin, erythromycin and roxithromycin 
have been shown to inhibit the OATP1B1 and -1B3-mediated uptake of pravastatin in in 
vitro studies (Jacobson 2004; Seithel et al. 2007; Bachmakov et al. 2008). Antidiabetic 
drug rosiglitazone, on the other hand, has been found to stimulate pravastatin uptake in 
vitro (Bachmakov et al. 2008). This finding suggests that also drug-induced stimulation 
of OATP1 mediated transport could cause alterations in drug plasma concentrations. 
Elevated statin plasma concentrations caused by OATP-mediated DDIs increase the risk 
for statin-induced side effects, such as myopathy and rhabdomyolysis (Thompson et al. 
2003; Generaux et al. 2011). Moreover, the uptake of statins into hepatocytes is 
essential for their inhibitory action of microsomal HMG-CoA reductase (Dansette et al. 
2000). Thus, reduced hepatic uptake of statins may also lead to decreased drug efficacy.  
 
Knowledge on the drug-drug interactions of the third basolateral SLCO transporter 
OATP2B1 is much more partial than for OATP1B1 and -1B3 (Fahrmayr et al. 2010). 
Only a few drugs have been identified as OATP2B1 substrates compared to OATP1B1 
and -1B3 (Tamai et al. 2000; Kopplow et al. 2005; Grube et al. 2006). One in vitro 
study by Noe et al. (2007) showed that gemfibrozil, fibrate used to treat 
hypercholesterolemia, inhibited OATP2B1-mediated uptake at high concentrations. 
 
Overall, inhibition of OATP-mediated hepatic uptake may have a substantial effect on 
drug disposition, safety and efficacy together with other causes of drug interactions, 
such as inhibition or induction of metabolizing enzymes. The clinical relevance of 
OATP1 inhibition depends on the contribution of OATPs to the total hepatic clearance 
and overall drug disposition of substrate drugs (Shitara et al. 2013). OATP1 substrates 
can be also substrates of other transporters and transporters may have multiple binding 
sites, which makes the estimation of the transporter contribution more complex.   
 
3.3 Pharmacogenetics and Interindividual Variability 
 
Apart from drug-drug interactions, also genetic polymorphisms in OATPs affect the 
pharmacokinetics of substrate drugs causing interindividual variability in drug response 
12 
  
 
and safety. Similar to DDIs, altered activity of OATP transporters caused by genetic 
variations can result in undesirable systemic exposure of substrate drugs which may 
lead to drug accumulation and organ toxicity (Giacomini et al. 2013). Over 40 single-
nucleotide polymorphisms (SNPs) have been identified in the SLCO1B1 gene coding 
OATP1B1 (Tirona et al. 2001; Fahrmayr et al. 2010). The effect of genetic variations on 
the OATP1B1-mediated transport of HMG-CoA reductase inhibitors has been 
investigated in numerous studies both in vitro and in vivo (Kameyama et al. 2005; 
Pasanen et al. 2006; Deng et al. 2008; Rodrigues et al. 2011). Significant interindividual 
differences in plasma concentrations have been reported for statins such as atorvastatin, 
simvastatin and pravastatin (Niemi et al. 2004; Pasanen et al. 2006; Niemi et al. 2006; 
Deng et al. 2008). Niemi et al. demonstrated also that reduced uptake of pravastatin in 
patients expressing mutated OATP1B1 proteins caused significantly lower 
pharmacological effect on cholesterol synthesis (Niemi et al. 2005). Decreased hepatic 
uptake and elevated plasma concentrations caused by OATP1B1 polymorphisms have 
been reported also for several other drugs than statins, such as ezetimibe, repaglinide, 
lopinavir and methotrexate (Oswald et al. 2008; Kalliokoski et al. 2008; Hartkoorn et al. 
2010; Ramsey et al. 2012). 
 
Polymorphisms in the genes coding OATP1B3 and OATP2B1 have not been as 
comprehensively studied (Fahrmayr et al. 2010; Schwarz et al. 2011). Recent study by 
Nies et al. (2013) suggests that the expression of OATP1B3 and OATP2B1 is not 
significantly influenced by genetic variants but interindividual variability of these 
transporters is caused by non-genetic factors. In addition to genotype, number of other 
factors such as gender, age, disease state or the regulation of transporter expression may 
be causes of interindividual variability in transporter action. In the study by Nies et al. 
(2013), liver condition cholestasis resulted in reduced OATP1B1 and -1B3 expression 
levels in liver. Also a gender-related difference in pharmacokinetics of pravastatin has 
been reported in a study that compared the effects of OATP1B1 polymorphism on 
pharmacokinetics of pravastatin (Niemi et al. 2006). However, the current data about 
non-genetic factors in interindividual variability of OATP transporters is scarce and 
further studies are needed. Also the significance of polymorphisms in SLCO1B3 and 
SLCO2B1 genes remains unclear and needs to be further elucidated. 
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4 METHODS FOR EVALUATION OF DRUG INTERACTIONS WITH UPTAKE 
TRANSPORTERS 
 
4.1 OATP Transporters in Drug Development 
 
Screening for drugs for their ability to be transporter substrates and/or inhibitors is 
becoming more and more common in drug development process due to the growing 
knowledge on the impact of transporters on pharmacokinetics and unpredictable 
variation in drug efficacy and toxicity. In addition to predicting interindividual 
variability caused by polymorphisms and DDIs, characterization of transporter substrate 
drugs helps to understand the contribution of saturable transport processes in the overall 
drug disposition (Mizuno et al. 2003). In preclinical drug development, this can aid in 
the selection of dosing regimen.  
 
Recently, the International Transporter Consortium (ITC) and both European Medicines 
Agency (EMA) and United States Food and Drug Administration (FDA) have 
recommended investigating for potential OATP1B1 and -1B3 substrates and inhibitors 
in drug development when hepatic clearance of the drug is significant, e.g. hepatic 
elimination is more than or equal to 25 % of the total clearance (Giacomini et al. 2010; 
FDA 2012; EMA 2012). Currently available methods for screening of drugs for their 
ability to be substrates or inhibitors of transporters vary from membrane based in vitro 
assays to in vivo genetic knockout animal models (Table 2). Also computational models 
have been developed for screening of large databases. Methods have been developed for 
both efflux and uptake transporter studies. The methods applicable for studying uptake 
transporters such as OATPs will be discussed in more detail in following sections. 
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Table 2. Methods used for evaluation of drug-transporter interactions. 
Method Type Application in Drug Development 
In vitro methods  
Membrane based assays 
 
 
Membrane vesicular transport assay 
 
Screening of substrates/inhibitors of 
uptake/efflux transporters 
 
ATPase assay 
 
Evaluation of transport function of 
efflux transporters 
 
Photolabeling assay 
 
Evaluation of binding sites and 
affinities of efflux transporters 
Cell based assays 
 
 
Uptake assay 
 
Screening of substrates/inhibitors of 
uptake/efflux transporters 
 
Cytotoxicity assay 
 
Screening of inhibitors of 
uptake/efflux transporters  
 
Transcellular transport assay 
 
Evaluation of vectorial transport 
function of efflux and uptake 
transporters, permeation studies 
In silico methods  
Computational models 
 
Prediction of substrate and inhibitor 
binding to uptake/efflux transporters  
 
Pharmacokinetic models 
 
Calculation of kinetic parameters,  
in vitro/in vivo extrapolation of 
pharmacokinetic data 
Ex situ methods  
Isolated organ models 
 
Prediction of in vivo transporter 
binding and contribution to drug 
disposition 
In vivo methods  
Genetic/chemical knockout models 
 
Evaluation of physiological function 
of transporters and contribution to 
drug disposition 
 
Imaging 
 
Visualization of transporter function 
in vivo, qualitative and quantitative 
evaluation of transporter function 
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4.2 Membrane Based Assays 
 
Membrane based assays have been mainly used to characterize substrates and inhibitors 
of ATP-dependent ABC efflux pumps (Jedlitschky et al. 1997; Kis et al. 2009; Heredi-
Szabo et al. 2013). Only one membrane based assay, the membrane vesicular transport 
assay, can be used to identify substrates and inhibitors of uptake transporters. In the 
assay, membrane vesicles expressing transporters of interest with substrate binding site 
facing outwards are incubated in a buffer mixture containing the drug (Meier et al. 
1984). Substrates of the transporter are taken up into the vesicles and rapid filtration is 
used to separate the vesicles from the incubation solution. The test compound trapped 
inside the vesicles is retained on the filter and the transported molecules can be 
quantified by liquid chromatography / mass spectrometry (LC/MS), fluorescence 
detector or liquid scintillation counting. The membrane vesicles can be prepared from 
different sources such as transporter transfected or over-expressed cells and different 
tissue samples. NTCP function and substrates have been studied using rat liver 
sinusoidal membrane vesicles (Meier et al. 1984; Koopen et al. 1997). Since NTCP is a 
sodium dependent transporter, the assessment of NTCP activity is based on the 
difference of drug accumulation in the presence and absence of sodium. OATPs, 
however, are Na
+
-independent transporters which makes the method inapplicable for 
screening of OATP substrates. 
 
The membrane vesicular transport assay has the advantage of being relatively easy to 
conduct and feasible for high-throughput screening (Giacomini et al. 2010). It is an 
effective method to determine transporter functions and to define detailed kinetic 
analyses for substrate or inhibitor interaction. Its disadvantage is that highly lipophilic 
compounds may have non-specific binding to lipid membranes or high passive diffusion 
which may cause false negative results (Xia et al. 2007). In addition, membrane vesicles 
obtained from tissue samples may be problematic if they are not purified and contain 
many varied transporters. This may limit their usefulness for evaluating the interaction 
of a particular transporter with a given compound.  
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4.3 Cell Based Assays 
 
Cell based assays are often more labor intensive and time consuming than membrane 
based assays but they may provide more comprehensive information about drug-
transporter interactions due to intact cell structure and function. Cell based assay 
systems can be used for transporter substrate and inhibitor screening, assessment of 
transport mechanisms and transporter-mediated DDIs, and for determining the rate-
limiting step in trans-epithelial transport. 
 
4.3.1 Common Cell Models 
 
Array of cell based systems used in the transporter interaction studies include primary 
cells, sandwich-cultured primary hepatocytes, polarized cell lines without recombinant 
transporters, single- and multiple transfected cell lines and Xenopus laevis oocytes. 
Primary cells isolated from intact tissue express the full spectrum of transporters present 
in a particular tissue. They are useful in investigation of the mechanistic interplay 
between uptake and efflux transporters and metabolism, as well as clinically relevant 
drug interactions (Soars et al. 2009). However, the polarization of the cells is quickly 
lost after isolation and the expression and localization of transporters may change over 
time in cell cultures (LeCluyse et al. 1996; Yang et al. 2012). The polarity of primary 
hepatocytes can be regenerated when cells are cultured in a sandwich configuration 
between two layers of collagen gel (LeCluyse et al. 1994; Liu et al. 1999). Sandwich-
cultured hepatocytes can be used to estimate both hepatic uptake and efflux of drugs 
and in vivo biliary clearance.  
 
Immortalized polarized cell lines are used to study vectorial transport and they enable 
the measuring of flux of substrates in two directions (apical to basolateral and vice versa) 
(Giacomini et al. 2010). They are standard methods to evaluate intestinal absorption and 
blood-brain barrier permeation. Some of the most used cell lines are human colon 
epithelial cancer cell line Caco-2, Madin-Darby canine kidney cell line (MDCK) and 
pig kidney proximal tubule epithelial cell line (LLC-PK1).  Caco-2 cells express a large 
variety of transporters specific for intestinal epithelium while endogenous expression 
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level of transporters is low in MDCK and LLC-PK1 cells (Goh et al. 2002; Ahlin et al. 
2009). MDCK and LLC-PK1 cells are often transfected with a single or multiple 
recombinant transporters. Recombinant transporter cell lines can be used for 
quantitative drug transport studies and to investigate transporter polymorphisms and 
species differences in transporter function. Several recombinant MDCK cell lines 
expressing OATP transporters have been developed, including OATP1B1 and MRP2 
double transfected cells and OATP1B1, OATP1B3, OATP2B1 and MRP2 quadruple-
transfected cells (Kopplow et al. 2005; Matsushima et al. 2005). Although the 
endogenous expression level of MDCK and LLC-PK1 cells is low, the contribution of 
the endogenous transporters should also be taken into account when using transfected 
cell lines (Goh et al. 2002). 
 
Xenopus laevis oocytes are also widely used for transporter studies (Xia et al. 2007). 
Transporter mRNA or cDNA can be microinjected into oocytes and the cells perform 
the translation and post-translational modification which leads to appropriate transporter 
expression on the cell membrane (Sigel and Minier 2005). Oocytes have low 
endogenous transporter expression which makes them a good system for characterizing 
transporter substrates and inhibitors and determining kinetic analyses for drug-
transporter interactions (Sobczak et al. 2010). Similar to single- or multiple transfected 
mammalian cells, they can also be used to study transporter polymorphisms and species 
differences of transporters (Xia et al. 2007). However, disadvantage of oocytes is a 
rather short expression turnaround time of a transporter. In addition, oocyte systems are 
only suitable for medium throughput screening due to the arduous microinjection 
method.  
 
4.3.2 Uptake Assays 
 
The involvement of a given influx transporter in drug uptake can be assessed using 
uptake assays. In uptake assays, the amount of test compound accumulated in the 
transporter-expressing cell is measured and the relative contribution of transporter is 
assessed comparing the uptake into control cells (Xia et al. 2007; Soars et al. 2009). 
Either isolated cells in suspension or cells seeded in 96-well tissue culture plates can be 
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used. In a standard uptake assay, cells are incubated in a substrate buffer, followed by 
the removal of the buffer and washing of the cells. The cells are lysed and the amount of 
test compound accumulated in the cells is quantified. Homogenous samples of the 
incubation mixture are taken over time and the concentration-time data can be used to 
calculate kinetic parameters such as Km, Vmax and uptake clearance (CLuptake). 
Identification of substrates for a particular transporter can also be done by manipulating 
the ionic composition or pH of the incubation buffer if the transporter function is 
dependent on ion gradients or a given pH. This is a useful method for studying for 
example NTCP-mediated transport (Kouzuki et al. 1999). Uptake of the test compound 
is measured both in the presence and absence of Na
+
 and the difference of the uptake in 
the two buffers is attributed to NTCP-mediated uptake. As for inhibition studies, the 
inhibitory ability of the test compound can be determined by co-incubating the test 
compound with a fluorescent or radiolabeled probe substrate and observing changes in 
the cell accumulation of the probe substrate.  
 
Variations of the standard uptake assay are the oil-spin assay and the media-loss assay 
(Petzinger and Fückel 1992; Soars et al. 2007) (Figure 3). The oil-spin assay is similar 
to the standard assay with the exception that the sample taken from the incubation 
buffer is immediately centrifuged through an inert oil layer (Petzinger and Fückel 1992). 
The density of the oil layer is lower than that of the cells but higher than that of the 
medium. Thus, centrifugal filtration of the cells through the oil leads to efficient cell 
separation with very little extracellular fluid adhering to the cells. The test compound or 
probe substrate concentration is then measured as in the conventional assay. In the 
media-loss assay, the decreasing concentration of drug in the media over time is 
measured from the supernatant after centrifugation (Soars et al. 2007). Combining the 
media-loss assay with either the standard uptake assay or the oil-spin assay can provide 
even more accurate prediction of in vivo drug clearance. 
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Figure 3. Different uptake assay formats. Media-loss assay and oil-spin assay differ 
from the standard assay in a way cells are separated from the incubation buffer. 
Sampling is followed by rapid centrifugation and the formed supernatant and cell pellets 
are further analyzed (Soars et al. 2009).  
 
Human cryopreserved hepatocytes are a good cell model to study hepatic drug uptake 
since they express all the endogenous hepatic transporters. There can, however, be large 
interbatch differences in the uptake activities of cryopreserved hepatocytes (Shitara et al. 
2003). Another downside is their high price. For this reason, also cryopreserved rat 
hepatocytes are widely used in uptake studies, together with transporter expressing cells 
such as MDCK cells, human embryonic kidney 293 (HEK293) cells and Xenopus laevis 
oocytes. 
 
Uptake assays require multiple steps for washing or centrifuging, sample collection, 
transferring and processing. Thus, uptake assays have rather low throughput, especially 
if no fluorescent or radiolabeled substrates are used. One way to enhance the throughput 
is to use scintillation proximity assay (SPA) technology where transporter expressing 
cells are directly grown in Cytostar-T scintillating microplates (Bonge et al. 2000). 
Uptake of radiolabeled transporter substrates is measured in real time in a microplate 
scintillation counter as radioisotopes are transported into proximity with the scintillation 
plate base. The method has been used for transporter inhibitor identification using 
radiolabeled substrates of for example OATP1B1, OAT3 and OCT1 (Lohmann et al. 
2007). 
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4.3.3 Cytotoxicity Assay 
 
Another method for identifying transporter substrates and inhibitors is to measure the 
accumulation of cytotoxic compounds in cells. In the cytotoxicity assay, cytotoxic 
transporter substrates can be identified by comparing the IC50 (the concentration that 
inhibits the cell growth by 50 %) in control cells and cells expressing the transporter 
(Xia et al. 2007). Inhibitors of uptake transporters can be indirectly identified by their 
ability to decrease the cytotoxic effects of a known substrate, while inhibitors of efflux 
pumps can be identified by observing potential increase in the cytotoxicity (Xia et al. 
2007; Kis et al. 2009; Ding et al. 2011). Cytotoxicity assays are applicable for high 
throughput screening of transporter substrates but it is only usable for cytotoxic 
compounds. Inhibitor studies only give indirect results and the results are best to 
confirm with other methods. 
 
4.3.4 Transcellular Transport Assays 
 
The coordination of uptake and efflux transporters in vectorial transport across 
membranes can be studied using cell lines that co-express uptake and efflux transporters 
(Matsushima et al. 2005; Kopplow et al. 2005). Cell monolayers are cultured on a 
Transwell insert membrane until they are differentiated and form a confluent monolayer 
of polarized cells. The transport assay system consists of a cell monolayer on a porous 
film which separates two fluid compartments representing the apical and basolateral 
sides of the cell (Figure 4). The substrate solution containing the test compound can be 
added either to the apical (upper) chamber or the basolateral (lower) chamber depending 
on the interest in apical-to-basolateral (A-to-B) or basolateral-to-apical (B-to-A) 
transport. Samples are taken from the receiving side and the cumulative amount of drug 
is plotted as function of time. If only passive diffusion affects permeation, the flux is 
assumed to be identical in both directions, but the participation of transporters results in 
saturable flux rate with increasing concentrations. 
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Figure 4. Transwell system used in transport assays. Upper chamber represents the 
apical side and lower chamber represents the basolateral side (Xia et al. 2007). 
 
Double or multiple transfected cell lines can be used to demonstrate the contribution of 
an individual transporter to hepatic excretion. For example, the vectorial transport of 
OATP1B1 and OATP1B3 substrate olmesartan was studied using three different 
doubly- transfected MDCKII cell lines (Matsushima et al. 2005). The efflux transporter 
MRP2 responsible for the hepatic excretion of olmesartan was identified conducting 
transport assays in OATP1B3/MRP2, OATP1B3/P-gp and OATP1B3/BCRP double 
transfectants.  Caco-2 cell monolayers are also used to investigate uptake and efflux 
transporter function using specific transporter inhibitors or probe substrates. However, 
transporter studies using Caco-2 cells may be non-specific due to the expression of 
multiple transporters in Caco-2 cells (Ahlin et al. 2009). There is also heterogeneity in 
transporter expression between different Caco-2 cell lines (Hayeshi et al. 2008). A 
novel approach to study the function of a particular transporter is to silence the 
expression of transporter genes by chemically synthesized RNA interference molecules 
(Yue et al. 2009). This method may enable the selective knock-down of endogenous 
transporter genes in mammalian cell lines. 
 
Transport studies with transfected cell lines may not be good for predicting in vivo drug 
disposition and clearance due to the lack of endogenous variety of uptake and efflux 
transporters and metabolizing enzymes. Drugs may be substrates of multiple uptake and 
efflux transporters in intact organs and therefore transfected cells might not provide 
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knowledge on the complete mechanism for trans-cellular transport (Bartholome et al. 
2007). Even Caco-2 cells that express multiple intestinal transporters vary in the 
transporter expression profile compared with primary intestinal epithelial cells 
(Taipalensuu et al. 2001). However, transport studies with Caco-2 cells provide a rather 
good method for prediction of drug intestinal permeability.  
 
4.4 In Silico Methods 
 
In silico modeling can be used in the early drug discovery and development phases as 
high-throughput methods to screen lead molecules for their potential to be transporter 
inhibitors and substrates. Together with in vitro methods, they aid in choosing 
compounds that have favorable characteristics for further development. In the 
preclinical phase, pharmacokinetic modeling is used to predict pharmacokinetics in 
humans and relationships between saturable active and passive transport can be 
examined in detail. 
 
4.4.1 Computational Modeling 
 
Computational modeling methods fill the gap between in vitro transporter properties 
and the knowledge on structural mechanisms of transporters on atomic level. They offer 
tools to predict ligand- and inhibitor-binding to transporters and to screen large 
databases for possible transporter substrates. In silico methods can be divided into 
structure-based approaches and substrate-based techniques (Chang and Swaan 2006). 
Structure-based models, such as homology or comparative modeling, are used to 
generate three-dimensional models of transporters based on available crystallographic 
data of appropriate template proteins. Homology and comparative models are based on 
the mutual sequence similarity of a template protein and the target protein. The model is 
usually constructed by applying the structural information of a template protein in the 
generation of a three dimensional structure of the target protein.   
 
Substrate-based models, such as pharmacophore and 3D-QSAR (quantitative structure-
activity relationship) modeling, are used to describe transporter protein’s structural 
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requirements for substrate or inhibitor interaction by correlating the biological activity 
of substrates and inhibitors with their molecular characteristics (Chang and Swaan 
2006). Pharmacophore models can give information about the binding or inhibition 
process and help in designing more compounds interacting with transporters. They are 
also useful for large database screening to identify new transporter ligands. 3D-QSAR 
models can be used to assist the design of more potent transporter inhibitors or 
substrates with higher affinity. Pharmacophore and 3D-QSAR models have been 
generated for transporters such as P-gp, OCTs, OATs and PEPT1 (Biegel et al. 2005; 
Diao et al. 2010; Broccatelli et al. 2011; Duan et al. 2012). High throughput screening 
based on computational models is cost-effective and may help to reduce experimental 
efforts in the early phases of drug development. Downside of computational models is 
that most models can only be used to screen inhibitors, not substrates.  
 
4.4.2 Pharmacokinetic Models 
 
Pharmacokinetic models are widely used tools to describe and predict the processes of 
drug disposition in vivo using data gathered from in vitro studies. Models can be divided 
into empirical and mechanistic based on their approach (Yu and Wilson 2010). 
Empirical models describe relationships between drug exposure and effect without 
consideration of the underlying mechanisms. Mechanistic models, on the other hand, 
are based on these physiological mechanisms and they can be used to describe the 
interplay of multiple processes that affect drug disposition in different tissues. A model 
describing hepatic clearance can be used for simultaneous assessment of uptake, passive 
diffusion, intracellular binding, and metabolism using data gathered from experimental 
in vitro assays.  Simple two-compartment models have been generated to study the 
hepatic uptake kinetics and metabolism of OATP substrates (Poirier et al. 2008; 
Menochet et al. 2012a). They enable the analysis of the whole in vitro data set in one 
step and can be used to quantify time-dependent nonlinearities of transporter uptake that 
are important in determining kinetic parameters of transporter substrates. A two-
compartment model has also been used to study interspecies and interindividual 
differences between uptake of OATP substrates in rat and human hepatocytes 
(Menochet et al. 2012b). 
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Physiologically based pharmacokinetic (PBPK) modeling is a mechanistically based 
approach that integrates drug-dependent and human physiology-dependent parameters 
(Yu and Wilson 2010). PBPK models describe the body by incorporating parameters 
corresponding to tissue and organ volumes, blood-flow rates, drug transporters and 
metabolizing enzymes. Drug-dependent parameters include molecular weight, solubility, 
particle size, pKa, logP and plasma protein binding. The in vivo pharmacokinetic profile 
of a compound can be simulated for different species by using species dependent 
parameters available in the literature. In addition to providing predictions of human 
pharmacokinetics, PBPK models are also useful tools for predicting the relative 
importance of uptake and efflux transporters in the drug disposition, as well as 
transporter-mediated drug-drug interactions in vivo. For example, the effects of changes 
in OATP1B1 activity on systemic and hepatic exposure of pravastatin has been 
simulated using a PBPK model that includes blood, liver and peripheral organs 
(Watanabe et al. 2009). Also a PBPK model to predict DDIs of pravastatin caused by 
OATP1B1 inhibitors, cyclosporine, gemfibrozil and rifampicin has been recently 
established (Varma et al. 2012). 
 
Overall, PBPK modeling has been shown to be a powerful tool to extrapolate animal 
pharmacokinetic data to humans. Compared to allometric approach, in which body 
weight of different animal species is used to extrapolate pharmacokinetic parameters to 
humans, PBPK modeling has proven to be produce more precise predictions of human 
pharmacokinetics (Kirman et al. 2003; Strougo et al. 2012). Both EMA and FDA 
recommend the use of PBPK models in the prediction of transporter-mediated drug-
drug interactions (FDA 2012; EMA 2012). The limitation of PBPK modeling is that it 
requires intense resources to generate the data on the various parameters described in 
the models.  
 
4.5 Intact Organ and in Vivo Models  
 
Models utilizing intact organs or live animals provide information about physiological 
functions and effects of transporters and are used as tools to predict pharmacokinetics of 
drugs in humans. Compared to in vitro methods, isolated organs or in vivo models allow 
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a more accurate determination of transporter contribution in absorption, hepatic 
elimination, renal excretion and brain penetration. Isolated and perfused organs are a 
good tool to study transporter function in a given tissue because the concentration of the 
drug in the organ can be controlled and the effect of other organs is eliminated (Xia et al. 
2007). By using specific transporter inhibitors, contribution of a given transporter to the 
pharmacokinetic profile can be assessed. For example, contribution of Oatp transporters 
in hepatic clearance of digoxin and atorvastatin has been examined in rat liver perfusion 
studies using rifampicin and rifamycin as selective Oatp inhibitors (Lau et al. 2004; Lau 
et al. 2006; Weiss et al. 2008). In live animals, the conventional method to study drug 
pharmacokinetics and distribution is to collect blood, urine and tissue samples after the 
administration of radiolabeled or non-labeled drug (Jaisue et al. 2010; van de Steeg et al. 
2011). The amount of accumulated drug in the samples can then be analyzed. In order to 
get a pharmacokinetic profile, samples are taken or animals are sacrificed at different 
time points.  
 
4.5.1 Genetic and Chemical Knockout Models 
 
Genetic knockout mice and naturally-occurring transporter-deficient animals are widely 
used to investigate the physiological function of a specific targeted transporter. Genetic 
knockout mice are generated by disrupting the endogenous transporter gene while 
natural mutant animals have a spontaneous mutation in a transporter gene. Spontaneous 
mutations of P-gp and Mrp2 genes have been identified in subpopulations of mice, rats 
and dogs (Buchler et al. 1996; Lankas et al. 1997; Mizukami et al. 2012). Genetic 
knockout of numerous different uptake and efflux transporter genes has been used to 
investigate the physiological contribution of transporters on drug absorption, tissue 
distribution and elimination (Xia et al. 2007; Giacomini et al. 2010). Recently, studies 
on Oatp1 (Slco1a/1b-/-) knockout mice have been used to investigate the impact of 
Oatp1 transporters on in vivo disposition of anticancer drugs paclitaxel and 
methotrexate and antihistamine fexofenadine (van de Steeg et al. 2010; van de Steeg et 
al. 2011). Also humanized transgenic mice expressing human OATP1B1, OATP1B3 
and OATP1A2 transporters instead of endogenous Oatp1a and -1b transporters have 
been generated (van de Steeg et al. 2009). Van de Steeg et al. have studied the 
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pharmacokinetics of methotrexate and paclitaxel also in the humanized transgenic mice 
(van de Steeg et al. 2013). 
 
Limitations of knockout and mutant models include species, strain, sex, diet and 
housing condition differences which have to be taken into consideration when 
interpreting data and extrapolating findings across species (Giacomini et al. 2010). 
Strain and gender differences in transporter expression have been reported and there are 
definitive species differences in transporter expression, function, substrate affinity and 
interplay between transporters and metabolizing enzymes (Merino et al. 2005; Li et al. 
2008). Humanized transporter animal models can at least partly help in translation of 
preclinical in vivo data to the clinical phase. Another problem in both knockout models 
and humanized transporter animal models is that deletion or addition of one transporter 
may cause changes in the expression of other transporters or enzymes and in the 
physiology of the animal (Lam et al. 2005; van de Steeg et al. 2010). These potential 
changes have to be taken into consideration when pharmacokinetics or toxic effects of 
drugs are assessed. 
 
Also chemical knockout of transporters using transporter inhibitors can be used to 
evaluate transporter function in drug disposition. Mice or rats are treated with a 
selective transporter inhibitor and the pharmacokinetics of test compounds are 
investigated in the presence of the inhibitor. Selective uptake inhibitors are available for 
P-gp and BCRP but so far no specific inhibitors for uptake transporters have been 
identified (Allen et al. 2002; Shepard et al. 2003). Chemical and genetic knockout 
models can also be combined. The selection of appropriate dose of the inhibitor is 
important in order to achieve inhibitory effect in vivo. The specificity of the transporter 
inhibitor is also important and the limitation of chemical knockout models is that it may 
be hard to find inhibitors that inhibit specifically only one type of transporters. 
 
4.5.2 Imaging 
 
Imaging techniques are used to visualize transporter functions in vivo and to 
qualitatively and quantitatively evaluate the role of transporters in humans. Positron 
27 
  
 
emission tomography (PET) and single photon emission computed tomography (SPECT) 
are non-invasive methods that can be used for accurate measurement of 
pharmacokinetic end points in animals and humans by detecting radioactivity emitted 
by radiolabeled tracers (Fischman et al. 2002). Utilization of genetic knockout mice and 
specific transporter inhibitors in imaging studies can help to evaluate the impact of a 
given transporter. For example, PET has been used to evaluate hepatobiliary transport 
of OATP1B1 and OATP1B3 substrates in humans with or without OATP1 inhibitor 
rifampicin administration (Takashima et al. 2012). Using rifampicin-treated mice and 
genetic knockout mice unable to express the uptake transporters Oatp1a/1b or Mrp2, the 
hepatic uptake and biliary efflux of was recently studied using SPECT imaging (Neyt et 
al. 2013). The study showed that the hepatic uptake and efflux of (99m)Tc-mebrofenin 
was impaired in Slco1a/1b and Abcc2 knockout mice, respectively. Rifampicin 
administration had similar effect on hepatic uptake and efflux. The results demonstrated 
that hepatic uptake and biliary efflux can be quantified simultaneously in vivo using 
imaging techniques. Also species differences in drug transport can be studied using 
imaging techniques. The whole-body distribution and OATP1B3/Oatp1 mediated 
hepatic transport of antihypertensive drug telmisartan in humans and rats have been 
studied by Shimizu et al (2012).  
 
The drawbacks of imaging techniques include the lack of useful probes for in vivo 
functional characterization of many transporters and the inability to distinguish the 
parent drug from its metabolites (Fischman et al. 2002; Takashima et al. 2012). Many 
imaging techniques can also be rather expensive and specialized experts of organic 
radiochemistry are required for PET and SPECT imaging. However, molecular imaging 
methods can significantly accelerate the drug development process by substituting time-
consuming dissection and tissue analysis (Rudin and Weissleder 2003). Also, multiple 
physiological or functional parameters can be obtained in a single study and 
longitudinal studies can be conducted using the same animal. In addition to decreasing 
the number of animals needed, this increases the statistical relevance of a study as each 
animal serves as its own control. The pharmacokinetic data collected in preclinical 
imaging supports clinical dose decisions by establishing evidence of the in vivo 
biological activity and safety profile of the lead compounds. 
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5 AIM OF THE STUDY 
 
The aim of the experimental part of the master’s thesis was to determine if entacapone 
and fluvastatin are actively transported from blood into rat and human hepatocytes 
through the sinusoidal membrane, and to assess the role of OATP transporters in the 
hepatic uptake of the drugs of interest.  
 
 
6 MATERIALS AND METHODS 
 
6.1 Drugs and Chemicals 
 
6.1.1 Entacapone and Fluvastatin 
 
Sodium salt of fluvastatin was purchased from Cayman Chemical Company (Ann Arbor, 
MI, USA). Entacapone was provided by Orion Pharma (Espoo, Finland). Properties of 
entacapone and fluvastatin are summarized in Table 3. 
 
Table 3. Properties of entacapone and fluvastatin (Noe et al. 2007; Varma et al. 2011; 
Greupink et al. 2011). 
 Entacapone Fluvastatin 
Structure 
 
 
 
MW 305,29 411,47 
Solubility Lipophilic  Lipophilic  
Hepatic 
transporter 
binding 
No published data 
OATP1B1, OATP1B3, 
OATP2B1, NTCP 
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Uptake studies with entacapone were performed with concentration range of 1 - 400 µM. 
Fluvastatin was used in the uptake studies with a concentration range of 1 - 50 µM. 
Substrate solutions were prepared in Krebs-Henseleit buffer (KHB), unless Na
+
 -free 
choline buffer was used in the experiment, in which case corresponding buffer was used 
in substrate solutions.  
 
7.1.2 Model Substrates 
 
Taurocholic acid (taurocholate) and estrone 3-sulfate (E3S) were used as model 
substrates of Oatp1 and Ntcp transporters. For quantification purposes, model substrate 
solutions contained 1 % (V/V) of 
3
H-labeled model substrate. E3S was used in 
competitive studies together with non-radiolabeled compounds. Estrone 3-sulfate 
sodium salt and taurocholic acid sodium salt hydrate were purchased from Sigma-
Aldrich (Buchs, Switzerland), whereas [
3
H]-estrone-3-sulfate ammonium salt with a 
specific activity of 57,3 Ci/mmol and [
3
H]-taurocholic acid with a specific activity of 5 
Ci/mmol were purchased from Perkin Elmer (Waltham, MA, USA).   
 
7.1.3 Control Compounds 
 
Sodium salt of rifamycin SV was used in the experiments as a broad Oatp1 inhibitor in 
order to rule out the effect of Oatp1-mediated active transport on the uptake of the 
investigated compounds. Highly lipophilic β-blocker (±)-propranolol hydrochloride was 
used as a control compound for passive transcellular permeation. [
3
H]-inulin (specific 
activity 0,25 µCi/ml) was used as a non-permeable control compound. As a 
polysaccharide with high molecular weight, inulin does not pass through most cell 
membranes (Middleton 1977; Duff et al. 2002). Rifamycin, propranolol hydrochloride 
and [
3
H]-inulin were purchased from Sigma-Aldrich (Buchs, Switzerland). 
 
7.1.4 Hepatocyte Medium 
 
Krebs-Henseleit buffer (KHB) was used to maintain hepatocyte viability during the 
uptake experiments. KHB was prepared in Milli-Q water, and it consisted of 142 mM 
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sodium chloride, 1,20 mM anhydrous magnesium sulfate, 0,96 mM potassium 
phosphate monobasic, 4,83 mM potassium chloride, 5 mM D-glucose, 1,53 mM 
calcium chloride dehydrate and 12,5 mM 4-(2-hydroxyethyl)-piperazine-1-
ethanesulfonic acid (HEPES), all from Sigma-Aldrich (Buchs, Switzerland), and 23,8 
mM sodium bicarbonate (J.T. Baker, Phillipsburg, NJ, USA). pH was adjusted to 7,4 by 
using 2 M sodium hydroxide (Reagena, Toivala, Finland). Solution was sterilized by 
filtration using a Nalgene bottle top filter with 0,2 µm pore size (Apogent Technologies, 
Rochester, NY, USA). 
 
Na
+
 -free choline buffer was used instead of KHB in one experiment in order to rule out 
the effect of Na
+
 -dependent active transport. The composition of choline buffer was the 
same as that of Krebs-Henseleit buffer except that sodium chloride and sodium 
bicarbonate were replaced by choline chloride  (Fluka Biochemika, Buchs, Switzerland) 
and  tris(hydroxymethyl)aminomethane (Tris base) (Sigma-Aldrich, Buchs, 
Switzerland), respectively. 
 
7.2 Hepatocytes 
 
To evaluate the difference in uptake kinetics between murine and human hepatocytes, 
both rat and human hepatocytes were used in the study. Due to limited availability of 
freshly isolated hepatocytes, part of the experiments with rat hepatocytes were 
conducted using cryopreserved cells, as were all of the experiments with human 
hepatocytes.  
 
The cryopreserved cells used in the study were pooled male Wistar rat hepatocytes and 
human hepatocytes from one female donor. Both rat and human hepatocytes were 
purchased from Celsis IVT (Baltimore, MD, USA). Before the experiments, 
cryopreserved cells were thawed in 37 °C water bath long enough to melt the solution 
and mixed with pre-warmed thawing medium (InVitroGRO™ HT, Celsis IVT, USA). 
After centrifugation at 600 rpm for 5 minutes (Heraeus Megafuge 1.0, Thermo Fisher 
Scientific, USA) and removal of the supernatant, hepatocytes were diluted to pre-
warmed KHB to a density of 2 x 10
6
 cells/ml. Hepatocytes were calculated and viability 
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was determined microscopically (Olympus CK40-F200, Tokyo, Japan) by eosin Y 
staining using a hemocytometer. Cell suspension was stored on ice until needed, and the 
uptake studies were conducted in a time period no longer than 2 hours after the 
hepatocytes were thawed. 
 
Fresh rat hepatocytes were isolated from eight-week-old male Wistar rats (HanTac:WH 
strain, Taconic Europe, Denmark) by a two-step in situ collagenase perfusion method 
(Berry and Friend 1969). Cell viability was determined by eosin Y staining. Liver 
perfusion and cell isolation of the freshly isolated hepatocytes was conducted by 
qualified personnel. Isolated cells were diluted to a density of 2 x 10
6
 cells/ml with cold 
KHB and stored on ice until needed. Uptake studies were conducted no longer than 4 
hours after the liver perfusions. 
 
7.3 Cellular Uptake Experiments 
 
To characterize the uptake kinetics of the compounds of interest, uptake experiments 
were performed using the oil-spin method (Yabe et al. 2011). Substrate associated with 
the hepatocytes was measured after separation from free substrate by a rapid 
centrifugation of the substrate solution over an inert silicone/mineral oil layer covering 
an alkaline solution layer (Figure 5).  
 
 
 
Figure 5. Flow chart of hepatocyte uptake assay using the oil-spin method (Xia et al. 
2007). 
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Prior to the start of the assays, the hepatocyte solutions were preincubated on an orbital 
shaker (Heidolph Titramax 100, Schwabach, Germany) at 37 °C for 15 minutes. The 
uptake assay was initiated by adding equal volume of hepatocyte solution to prewarmed 
substrate solution. The reaction mixture was incubated at 37 °C on a thermoblock (700 
rpm) (Eppendorf Thermomixer Comfort, Hamburg, Germany). In each experiment, 
incubations were carried out in triplicate. To determine intracellular and extracellular 
concentrations, 100 µl aliquots of the reaction mixture were pipetted into 
microcentrifuge tubes containing 100 µl 2 M NaOH covered by 100 µl of silicone-
mineral oil (BD Gentest, San Jose, CA, USA). At designated time points (30, 90, and 
180 s), the reaction was terminated by centrifuging the samples at 14 000 rpm for 30 
seconds in a tabletop microcentrifuge (Eppendorf MiniSpin Plus, Hamburg, Germany). 
After separation of cells from the media, the tubes were kept on ice before freezing at    
-20 ºC. For normalization of the uptake activity, 100 µl of each reaction mixture was 
added to 100 µl of NaOH without oil filtration in order to measure the total radioactivity 
in 100 µl of each reaction mixture. Samples were stored at -20 ºC before sample 
preparation. 
 
Uptake experiments for the non-radiolabelled substrate solutions of fluvastatin and 
entacapone were performed as described for radiolabelled compounds, with the 
exception that 5 M ammonium acetate solution was used as the bottom layer instead of 
sodium hydroxide. 
 
7.4 Sample Preparation 
 
7.4.1 Sample Preparation for Liquid Scintillation Analysis 
 
Frozen microcentrifuge tubes were cut in the center of the oil layer and the bottom 
halves containing the cell pellets were placed into scintillation vials. After cutting, cell 
samples were allowed to sit in room temperature for 1-2 hours in order to let NaOH 
dissolve the hepatocytes, followed by the addition of 100 µl of 2 M hydrogen chloride 
(Reagena, Toivala, Finland) to neutralize the samples. Scintillation cocktail (Ecoscint A, 
National Diagnostics, Atlanta, GA, USA) was then added to the vials and cell 
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suspension was pipetted out of the microcentrifuge tubes and mixed with the 
scintillation cocktail by vortex and manual pipetting.  
 
For measurement of extracellular substrate concentration, top halves of the 
microcentrifuge tubes containing the supernatant were collected into scintillation vials. 
Supernatant samples were pipetted out of microcentrifuge tubes inside the vials and 
mixed with scintillation cocktail.  
 
7.4.2 Sample Preparation for UPLC/MS Analysis 
 
Non-radiolabelled samples of fluvastatin and entacapone were prepared for ultra 
performace liquid chromatography / mass spectrometry (UPLC/MS) analysis. Aliquots 
were pipetted from the upper supernatant samples, pipetted into eppendorfs and diluted 
with methanol. Microcentrifuge tubes were then cut as previously described, after which 
bottom samples were pipetted into eppendorfs. Samples were precipitated with 100 µl 
of methanol (J.T. Baker, Phillipsburg, NJ, USA) and centrifuged at 14 000 rpm for 5 
minutes. The supernatants were pipetted into UPLC vials.  
 
7.5 Quantification and Metabolite Screening 
 
7.5.1 Quantification of Radiolabeled Samples 
 
Radiolabelled samples were analyzed using a liquid scintillation counter (Perkin Elmer 
Wallac 1414, Waltham, MA, USA). Quantification was performed by first calculating 
the average radioactivity (decays per minute, DPM) per pmole of model substrate in 
100 µl of reaction mixture, and comparing this value to the radioactivity of each sample. 
 
7.5.2 Quantification of Non-Radiolabeled Samples 
 
Non-radiolabeled samples were analyzed using Waters Acquity UPLC system (Milford, 
MA, USA) coupled to Sciex API 4000 triple quadrupole MS detector (Foster City, CA, 
USA). For entacapone samples, separation was accomplished with a 2,1 x 50 mm 
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UPLC BEH C18 column (Waters, Milford, MA, USA). For fluvastatin samples, 
separation was done with a 2,1 x 100 mm Purospher Star Hibar C18 column (Merck, 
Darmstadt, Germany). Chromatographic conditions for both compounds are 
summarized in Table 5.  
 
Table 5. Chromatographic conditions for entacapone and fluvastatin. 
 Entacapone Fluvastatin 
Mobile Phase A 0,1 % Formic acid, pH 3 0,1 % Formic acid, pH 3 
Mobile Phase B Acetronitrile Acetonitrile/Methanol 
50:50 (V/V) 
Column 
Temperature (°C) 
 
55 50 
Flow Rate (µl/min) 800 400 
Gradient Run 
95-10 % B  in 3 min, 
hold 0,5 min, then to 95 % 
B over 0,1 min 
30 % A 70 % B 
 
The quantification of the test compounds in the samples was performed by comparing 
the samples’ peak areas to a calibration curve plotted with a set of external standards. 
Fluvastatin standard curve ranged from 10 nM to 10 µM. Entacapone standard curve 
ranged from 10 nM to 50 µM. 
 
7.5.3 Fluvastatin Metabolite Screening 
 
The presence of main metabolites of fluvastatin in cell and supernatant samples was 
investigated in UPLC/MS/MS analysis using the same devices and chromatographic 
conditions as for fluvastatin quantification. The concentration of metabolites in the 
samples was not quantified. 
 
7.6 Data Analysis 
 
The initial uptake velocity (V) of test compounds was determined from the slope of the 
plot of substrate amount in hepatocytes versus time.  Initial uptake velocity values were 
used to calculate hepatic uptake clearance (CLuptake) by dividing by substrate 
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concentration in the reaction mixture. Passive uptake rate (Pdiff), Michaelis-Menten 
constant (Km) and maximum uptake rate (Vmax) were calculated by simultaneous fitting 
of all time and concentration points using nonlinear regression in GraphPad Prism 
(GraphPad Sofware, San Diego, CA, USA) by using the following equation: 
 
   
      
     
          Equation 3 
 
where S is the substrate concentration in the reaction mixture. Total uptake clearance 
(CLuptake) included both the active (CLactive) and passive component (Pdiff). The saturable 
active hepatic uptake was estimated by Vmax/Km and the contribution of saturable uptake 
of the total uptake by using equation 4: 
 
The contribution of active hepatic uptake (%)  =   
        
               
      Equation 4 
 
The inhibitor concentration that corresponds to the 50% of the maximum inhibition of 
E3S uptake transport (IC50) was determined for rifamycin SV and entacapone by fitting 
the uptake clearance data to the following equation (5) using nonlinear regression in 
GraphPad Prism. 
 
                        (
    
       
)   Equation 5  
 
 
7 RESULTS 
 
7.1 Cell Viability and Non-Specific Binding  
 
The viability of cell suspensions used in the experiments ranged from 93 % to 79 % for 
freshly isolated rat hepatocytes, from 82 % to 68 % for cryopreserved rat hepatocytes 
and from 82 % to 72 % for cryopreserved human hepatocytes. After the experiments, 
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the viability of the cells had decreased to an average of 54 % with no significant 
difference between freshly isolated or cryopreserved hepatocytes. 
 
The integrity of the cells and non-specific binding to cell membranes was investigated 
with an oil-spin assay using cryopreserved rat hepatocytes and 1 µl/ml [
3
H]-inulin. Low 
amount of radioactivity was detected in the samples but the amount did not significantly 
change over time which indicates that inulin seemed to bind to the cells to a small 
degree without accumulation into the cells (Table 6).  
 
Table 6. Radiolabeled inulin in cell samples expressed as a percentage of the 
radioactivity in the reaction mixture. Cryopreserved rat hepatocytes were incubated with 
1 µl/ml [
3
H]-inulin at 3 different time points under 3 minutes. 
Time (s) Percentage of inulin in cell samples  
 Sample 1 Sample 2 Sample 3 avg ± std 
30 0,03 0,18 0,03 0,08 ± 0,09 
90 0,03 0,04 0,20 0,09 ± 0,10 
180 0,14 0,03 0,03 0,07 ± 0,07 
 
7.2 Kinetic Evaluation of Taurocholate, Fluvastatin and Entacapone Uptake 
 
A time-dependent increase in intracellular concentration and a concentration-dependent 
increase in uptake rate was observed for all the compounds investigated. The uptake 
rates of the investigated compounds mainly showed a decrease after 90 second time 
point, as is shown for taurocholate in Table 8.  
 
Table 8. Uptake rate of sodium taurocholate in freshly isolated rat hepatocytes 
calculated using time intervals from 30 seconds up to either 90 or 180 seconds. Values 
are represented as means of triplicate samples ± standard deviation. N = 1 
Taurocholate 
concentration (µM) 
V (pmol/min/10
6
 cells), 
30 s - 90 s 
V (pmol/min/10
6
 cells), 
30 s - 180 s 
1 109 ± 42,7 30,0 ± 10,1 
10 501 ± 247 299 ± 102 
25 888 ± 720 496 ± 200 
50 923 ± 1110 932 ± 497 
100 1470 ± 1240 1660 ± 961 
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Thus, the kinetic parameters were calculated using 30 and 90 second time points since 
this time interval seemed to represent the linear initial uptake velocity better than the 
time interval up to 180 seconds. 
 
In each experiment with multiple substrate concentrations, extracellular radioactivity 
was determined in supernatant samples of one concentration of taurocholate or estrone 
3-sulfate. Taurocholate and E3S amount in supernatant samples decreased in proportion 
to cellular uptake and the sum of radioactivity (dpm) detected in the cell and 
supernatant samples did not differ significantly from the radioactivity in reaction 
mixtures in any of the experiments, as is shown for 10 µM taurocholate in Table 7. 
 
Table 7. Combined radioactivity in supernatant and cell samples expressed as a 
percentage of the radioactivity in the reaction mixture. Freshly isolated rat hepatocytes 
were incubated with 10 µM [
3
H]-sodium taurocholate at 3 different time points under 3 
minutes. 
Time (s) Percentage of combined radioactivity in cell and supernatant 
samples  
 Sample 1 Sample 2 Sample 3 avg ± std 
30 104 101 99,9 102 ± 2,1 
90 103 104 100 103 ± 2,0 
180 104 101 100 102 ± 2,1 
 
Concentration-dependent uptake rates of taurocholate, fluvastatin, and entacapone in 
freshly isolated rat hepatocytes are represented in Figure 6, together with time curves of 
uptake. For entacapone, the UPLC method had a significant carryover effect. 
Consequently, the results for samples with lowest concentrations were not reliable and 
were not used in the calculation of uptake rate and clearance. Moreover, the quantified 
concentrations of entacapone and fluvastatin reaction mixtures were lower than they 
were prepared to be. The quantified concentrations were used to calculate the kinetic 
parameters of the drugs.  
 
Uptake rates of taurocholate and fluvastatin showed saturability with increasing 
concentrations, whereas entacapone uptake was linear and showed no saturability 
(Figure 6). At fluvastatin concentration 25 µM, V and CLuptake were negative in the time 
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interval up to 90 seconds. This data point was removed from nonlinear regression 
analysis in order to get reliable results. The uptake rates and clearances of taurocholate, 
fluvastatin and entacapone at different concentrations are summarized in Table 9. 
 
 
 
Figure 6. The uptake of sodium taurocholate (A,B), fluvastatin (C,D) and entacapone 
(E,F) into freshly isolated rat hepatocytes. The initial uptake rates (B,D,F) are calculated 
using 30 second and 90 second time points. Values are represented as means of 
triplicate samples ± standard deviation. N = 1 
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Table 9. Initial uptake rate and uptake clearance of taurocholate, fluvastatin and 
entacapone in freshly isolated rat hepatocytes. Values are represented as means of 
triplicate samples ± standard deviation. The quantified concentrations of entacapone and 
fluvastatin solutions are presented in parentheses. N = 1 
C 
(µM) 
V  
(pmol/min/10
6
 cells) 
CLuptake  
(µl/min/10
6
 cells) 
Taurocholate    
1  109 ± 42,7 109 ± 42,7 
10  501 ± 247 50,1 ± 24,7 
25  888 ± 720 35,5 ± 20,6 
50  923 ± 1110 18,5 ± 22,0 
100  1470 ± 1240 14,7 ± 12,4 
Fluvastatin    
1 (0,5)  101 ± 37,0 217 ± 79,2 
5 (2)  305 ± 100 176 ± 57,8 
10 (4)  500 ± 76,9 128 ± 19,6 
25 (9)  -173 ± 326 -19,1 ± 35,8 
50 (17)  533 ± 635 30,8 ± 36,7 
Entacapone    
1 (0,3)  < LOQ < LOQ 
3 (0,7)  < LOQ < LOQ 
10 (3)  546 ± 280 172 ± 88,2 
50 (30)  620 ± 990 24,7 ± 39,4 
100 (80)  1060 ± 578 17,5 ± 9,49 
200 (160)  4340 ± 1500 26,8 ± 9,25 
 
The uptake clearance of taurocholate differed in freshly isolated and cryopreserved rat 
hepatocytes. Uptake clearance was lower in cryopreserved hepatocytes with every 
concentration tested, while the relative decrease in clearance with increasing 
concentrations was larger in freshly isolated hepatocytes (Table 10). The uptake of 
taurocholate and entacapone was also investigated in cryopreserved human hepatocytes. 
The uptake clearance of both compounds was lower in human hepatocytes compared to 
freshly isolated rat hepatocytes (Table 10). For entacapone, the difference was more 
drastic. In rat hepatocytes, entacapone uptake clearance decreased somewhat linearily 
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with increasing concentrations, while in human hepatocytes uptake clearance seemed to 
stay at a constantly low level in the concentration range of 10 – 100 µM.  
 
Table 10. Uptake clearance of taurocholate and entacapone in freshly isolated and 
cryopreserved rat hepatocytes and cryopreserved human hepatocytes. Values are 
represented as means of triplicate samples ± standard deviation. N = 1, *Quantified C = 
3 µM, 30 µM, 80 µM **Quantified C = 5 µM, 26 µM, 70 µM 
 CLuptake in  
freshly isolated  
rat hepatocytes 
(µl/min/1e6 cells) 
CLuptake in 
cryopreserved  
rat hepatocytes 
(µl/min/1e6 cells) 
CLuptake in 
cryopreserved  
human hepatocytes 
(µl/min/1e6 cells) 
Taurocholate    
 1 µM 109 ± 42,7 27,9 ± 0,29 64,6 ± 8,74 
10 µM 50,1 ± 24,7 23,9 ± 25,8 12,7 ± 8,91 
25 µM 35,5 ± 20,6 17,9 ± 3,83 -- 
50 µM 18,5 ± 22,0 -- 4,01 ± 7,83 
100 µM 14,7 ± 12,4 1,32 ± 0,44 -- 
Entacapone    
10 µM 172 ± 88,2* -- 5,08 ± 5,67** 
50 µM 24,7 ± 39,4* -- 3,11 ± 1,61** 
100 µM 17,5 ± 9,49* -- 2,21 ± 1,75** 
 
The Michaelis-Menten constant (Km) was higher for taurocholate compared to 
fluvastatin, being 24 µM and 6 µM, respectively (Table 11). Also maximum uptake rate 
(Vmax) and passive uptake rate (Pdiff) were lower for fluvastatin. The saturable 
components for taurocholate and fluvastatin uptake were 82 % and 94 % of the total 
uptake, respectively. 
 
Table 11. Kinetic parameters for the hepatic uptake of taurocholate and fluvastatin in 
freshly isolated rat hepatocytes. Values represent the mean of triplicate samples and 
with standard error presented in parentheses. N = 1 
 Km 
µM 
Vmax 
pmol/min/ 
10
6
 cells 
Pdiff 
µl/min/ 
10
6
 cells 
Vmax/Km 
µl/min/ 
10
6
cells 
Taurocholate 24,49 (39,60) 1778 (793,7) 15,92 (446,5) 72,60 
Fluvastatin 5,82 (2,006) 1171 (114,6) 11,77 (57,84) 201,3 
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Goodness of fit and constraints for nonlinear regression analysis used in the calculation 
of parameters are summarized in Appendix 1. Respective kinetic parameters of 
entacapone could not be calculated due to the lack of saturability in the uptake data.  
 
7.3 Fluvastatin Metabolism 
 
In order to investigate the effect of metabolism on intracellular concentration of 
fluvastatin, cryopreserved rat hepatocytes were incubated in 10 µM fluvastatin solution 
and fluvastatin concentration in cell and supernatant samples was determined at six 
different time points during 15 minute time interval. Fluvastatin concentration in cell 
samples increased until 5 minute time point, being an average of 905 nM (Figure 7). At 
15 minute time point, fluvastatin concentration in cell samples had decreased to an 
average of 624 nM. Extracellular fluvastatin concentration decreased in proportion to 
fluvastatin uptake, with more rapid decrease in concentration during first 3 minutes of 
incubation. 
 
Figure 7. Comparison of fluvastatin concentration (µM) in the cell (●) and supernatant 
(■) samples during 15 minute incubation of cryopreserved rat hepatocytes in 10 µM 
sodium fluvastatin solution. Sum of fluvastatin (µM) in cell and supernatant samples 
(▲). Each symbol and vertical bar represent the mean ± STD of triplicate samples. 
 
Only very minor peaks for hydroxylated fluvastatin were detected in the LC/MS 
analysis of cell samples (Appendix 3). Slightly larger peak areas for hydroxylated 
fluvastatin were detected in supernatant samples, with larger peaks towards 15 minute 
time point. Also minor peaks for fluvastatin glucuronide were detected in the samples. 
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Peak areas of fluvastatin glucuronide were significantly lower in the cell samples 
compared to supernatant samples and peaks areas in either sample type did not increase 
towards the end of the incubation time. No peaks were detected for des-isopropyl-
fluvastatin and des-isopropyl-dihydro-fluvastatin tetranor.  
 
7.4 Inhibition Studies 
 
The net uptake, V and CLuptake of 1 µM [
3
H]-taurocholate in rat hepatocytes decreased 
in an inhibition study with 100 µM rifamycin. The sodium dependency of taurocholate 
uptake was observed when Na+ free choline buffer was used instead of KHB buffer. 
The net uptake and uptake rate of taurocholate slowed down in choline buffer compared 
to incubation in KHB buffer with or without rifamycin (Figure 8). A more prominent 
decline in uptake rate was detected when incubating taurocholate in choline buffer 
together with 100 µM rifamycin. The uptake clearance of 1 µM taurocholate decreased 
to 2,16 µl/10
6
 cells/min in the presence of Oatp1 inhibitor rifamycin and in the absence 
of sodium. 
 
 
Figure 8. The uptake of 1 µM [
3
H]-taurocholate in freshly isolated rat hepatocytes when 
incubated in KHB buffer (▼), in choline buffer (▲), in KHB buffer with 100 µM 
rifamycin (■), and in choline buffer with  100 µM rifamycin (♦). N = 1 
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The net uptake of 1µM [
3
H]-estrone 3-sulfate into rat hepatocytes was decreased when 
incubated with 50 µM propranolol or 50 µM entacapone but V and CLuptake did not 
change significantly (Figure 9). Similar to the inhibition study with taurocholate, 
incubation with rifamycin reduced the net uptake, V and CLuptake of E3S.  
 
 
Figure 9. Effect of propranol, entacapone and rifamycin on estrone 3-sulfate (E3S) 
uptake in freshly isolated rat hepatocytes. 1 µM E3S uptake was investigated with 
separate incubations with 50 and 100 µM rifamycin, 50 µM propranolol and 50 µM 
entacapone in rat hepatocytes. Values are represented as means of triplicate samples ± 
STD. N = 1 
 
The inhibitory effect of rifamycin on 1µM [
3
H]-E3S uptake was investigated with a 
concentration range of 1-100 µM in both freshly isolated and cryopreserved rat 
hepatocytes. Contrary to the experiments with taurocholate, E3S uptake kinetics did not 
significantly differ in cryopreserved and freshly isolated hepatocytes. Rifamycin 
concentrations of 1 µM and 10 µM did not have a notable effect on E3S uptake (Table 
9). However, CLuptake of E3S was reduced from an average of 95 µl/min/10
6
 cells to 42 
and 34 µl/min/10
6
 cells, when incubated with 50 µM and 100 µM rifamycin, 
respectively. 
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Table 9. Uptake clearance of 1 µM estrone 3-sulfate with rifamycin or entacapone in 
isolated rat hepatocytes. Values are represented as means of triplicate samples and 
individual experiments (N) ± STD, rifamycin N = 3, entacapone N = 1. *N = 1 
Inhibitor concentration  
µM 
CLuptake 
µl/min/10
6
 cells 
 Rifamycin Entacapone 
0  
1  
10  
50  
100  
200  
400 
95,07 ± 13,15 
87,06 ± 8,20 
97,17 ± 5,52 
42,28 * 
33,59 ± 5,90 
-- 
-- 
88,87 ± 14,36 
-- 
95,94 ± 9,32 
81,18 ± 14,17 
61,61 ± 10,35 
55,15 ± 3,31 
32,26 ± 3,14 
 
Entacapone inhibited the net uptake of 1µM [
3
H]-E3S into freshly isolated rat 
hepatocytes in the concentration range of 10-400 µM (Figure 10). V and CLuptake of E3S 
were inhibited with entacapone concentrations ranging from 100 to 400 µM (Table 9).  
 
 
Figure 10. Effect of on entacapone estrone 3-sulfate (E3S) uptake in freshly isolated rat 
hepatocytes. 1 µM E3S uptake was investigated with entacapone concentrations ranging 
from 10 µM to 400 µM. Values are represented as means of triplicate samples ± STD.  
N = 1 
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The 50% inhibitory concentration (IC50) values of rifamycin and entacapone for uptake 
of [
3
H]-estrone 3-sulfate in rat hepatocytes were 62 and 237 µM, respectively. 
Goodness of fit and constraints for nonlinear regression analysis used in the calculation 
of IC50 values are summarized in Appendix 2. The inhibitory effects of rifamycin and 
entacapone on saturable uptake clearance of E3S in rat hepatocytes are shown in Figure 
11. 
 
 
Figure 11. Comparison of the inhibition of 1 µM [
3
H]-estrone 3-sulfate uptake clearance 
by rifamycin (lower curve) and entacapone (upper curve) in isolated rat hepatocytes. 
Rifamycin concentration range was 1 to 100 µM and entacapone concentration range 
was 10 to 400 µM. Each symbol and vertical bar represent the mean ± STD of triplicate 
samples and individual experiments (N) ± STD, rifamycin N = 3, entacapone N = 1 
 
 
8 DISCUSSION 
 
8.1 Uptake Kinetics of Taurocholate and Estrone 3-Sulfate 
 
Taurocholate uptake kinetics observed in the study is in concord with the knowledge of 
the active transporter-mediated hepatic uptake process of taurocholate. The decrease in 
uptake rate after 90 second time point is similar to the observation of a previous study 
using the oil-spin method where uptake rate of taurocholate was determined at 15 
second intervals through the initial 120 seconds of incubation (Edmondson et al. 1985). 
Hepatic uptake of taurocholate has been shown to be mediated by sodium-dependent 
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manner by murine Ntcp and human NTCP transporters, as well as sodium-independent 
manner by murine and human organic anion transporters including Oatp1a1, Oatp1a4, 
Oatp1b2, OATP1B1 and OATP1B3 (Kullak-Ublick et al. 1995; Kouzuki et al. 1999; 
Eckhardt et al. 1999; Cattori et al. 2001). Incubation in Na
+
 free buffer appeared to 
cause a larger decrease in taurocholate uptake in rat hepatocytes compared to incubation 
with Oatp1 inhibitor rifamycin SV which indicates that sodium-dependent transport 
processes are mainly responsible of hepatic uptake of taurocholate. This finding is in 
accordance with previous data (Edmondson et al. 1985; Sandker et al. 1994).  
 
The Km value of 24 µM calculated for taurocholate is in good agreement to the results in 
other studies using freshly isolated and primary cultured rat hepatocytes in which Km for 
taurocholate varied between 17 to 24 (Edmondson et al. 1985; Sandker et al. 1994; 
Kouzuki et al. 1998).  The lower V and CLuptake of taurocholate in cryopreserved rat and 
human hepatocytes compared to freshly isolated rat hepatocytes indicates that 
taurocholate uptake was less efficient in cryopreserved rat and human cells. Houle et al. 
(2003) have studied the effect of cryopreservation on taurocholate uptake in rat 
hepatocytes and found no significant difference in taurocholate uptake between freshly 
isolated and cryopreserved cells. The difference observed in the present study may be 
caused by slight difference in cell viability between freshly isolated and cryopreserved 
cells and by the fact that no Percoll centrifugation was performed in order to remove 
dead cells when cell viability of the cryopreserved cells was lower than 85 %, as was 
done in the study by Houle et al. (2003). The lower hepatic uptake of taurocholate in 
cryopreserved human hepatocytes is in accordance with previous studies using both 
freshly isolated rat and human hepatocytes and cryopreserved human hepatocytes, 
indicating that there are species differences in the active transport mechanisms of bile 
acids (Sandker et al. 1994; Kouzuki et al. 1998; Shitara et al. 2003).  
 
The inhibitory effect of rifamycin SV on taurocholate and estrone 3-sulfate uptake in rat 
hepatocytes supports previous data about inhibition potency of rifamycin SV on murine 
Oatp and Ntcp transporters. High concentration (100 µM) of rifamycin SV has been 
reported to inhibit both sodium-dependent and sodium-independent taurocholate uptake 
in short-term cultured rat hepatocytes, whereas low concentration (10 µM) only 
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inhibited sodium independent taurocholate uptake (Fattinger et al. 2000). Rifamycin SV 
was shown to inhibit Ntcp, Oatp1a1 and Oatp1a4-mediated transport of taurocholate in 
Xenopus laevis oocytes. However, in a study using Oatp1b2 knockout mice, rifamycin 
SV did not exhibit significant liver uptake by Oatp1b2 (Chen et al. 2008). At rifamycin 
SV concentration of 100 µM, CLuptake of taurocholate and estrone 3-sulfate were 
decreased by 32 % and 65 %, respectively. The relatively higher inhibition of E3S 
uptake by 100 µM rifamycin compared to that of taurocholate suggests that sodium-
independent transport plays a more prominent role in hepatic uptake of E3S compared 
to that of taurocholate. This finding is in agreement with the knowledge that E3S is 
transported by all hepatic Oatp/OATP transporters but not Ntcp/NTCP (Cattori et al. 
2001; Kullak-Ublick et al. 2001). 
 
8.2 Fluvastatin Uptake and Metabolism 
 
Previously, hepatic uptake of fluvastatin has been shown to be mediated by OATP2B1, 
OATP1B1, OATP1B3 and NTCP (Kopplow et al. 2005; Noe et al. 2007; Greupink et al. 
2011; Varma et al. 2011). Unlike for simvastatin and pravastatin, genetic 
polymorphisms in the gene coding OATP1B1 have not been reported to result in 
decreased hepatic uptake of fluvastatin, suggesting that other transporters or passive 
diffusion are mainly responsible for the uptake (Niemi et al. 2006; Pasanen et al. 2006). 
This was confirmed in a study using double-transfected MDCKII cells expressing 
MRP2 together with OATP1B1, OATP1B3, or OATP2B1 (Kopplow et al. 2005). Km 
value for fluvastatin in MRP2-OATP2B1-expressing cells was significantly lower 
compared to MRP2-OATP1B1 and MRP2-OATP1B1-expressing cells, being 0,7, 2,4 
and 7,0, respectively. Lipophilic fluvastatin is also taken up into cells by passive 
diffusion but passive uptake has been reported to constitute only one tenth of the total 
uptake in primary cultured rat hepatocytes incubated at 4 °C and 37 °C (Ohtawa et al. 
1999). Consistent with this data, hepatic uptake has been reported to be the rate-
determining process in the overall hepatic elimination of fluvastatin in rats (Watanabe et 
al. 2010). 
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In the present study, fluvastatin uptake by murine transporters was investigated using 
freshly isolated rat hepatocytes. Saturable uptake kinetics with increasing concentration 
observed indicate active transport mechanism in hepatic uptake of fluvastatin in rats, 
which supports previous data by Ohtawa et al. (1999). Intracellular fluvastatin 
concentration seemed to reach a rather high value already at 30 second time point, after 
which uptake velocity appeared to slow down (Figure 6C). The apparent decrease in 
uptake rate might have been a result from rapid non-specific binding of lipophilic 
fluvastatin onto cell membranes but previous data about fluvastatin uptake kinetics do 
not support this hypothesis. In an uptake study using plated freshly isolated human 
hepatocytes, the uptake of fluvastatin was linear up to approximately 1 minute (Noe et 
al. 2007). The linearity of fluvastatin uptake up to 90 seconds of incubation in rat 
hepatocytes should be studied in future in order to confirm the reliability of the 
calculated kinetic parameters. The negative V and CLuptake observed at fluvastatin 
concentration of 25 µM were most likely caused by error in pipetting. Otherwise, 
deviation in concentrations of triplicate samples was small.  
 
The calculated Km (5,8 µM) for fluvastatin is slightly higher compared to the Km of 
fluvastatin (2,3 µM) in a study using MRP2-OATP1B1/1B3/2B1 quadruple-transfected 
MDCKII cells and significantly lower compared to Km of fluvastatin (37,6 µM) in 
primary cultured rat hepatocytes (Ohtawa et al. 1999; Kopplow et al. 2005). Passive 
diffusion comprised approximately 6 % of the total fluvastatin uptake which is less than 
in primary cultured rat hepatocytes. The higher Km and Pdiff for fluvastatin in primary 
cultured hepatocytes may have been caused by decreased expression of uptake 
transporters (Yang et al. 2012). Lower Km for fluvastatin in transfected cells expressing 
human OATPs suggest that sodium-independent saturable transport plays a more 
prominent role in hepatic uptake of fluvastatin in humans compared to rats. However, 
transfected cell models cannot always predict the uptake behavior in freshly isolated 
hepatocytes as the full spectrum of endogenous transporters is not expressed (Noe et al. 
2007). Further studies comparing fluvastatin uptake into isolated rat and human 
hepatocytes are needed to get a full view of inter-species differences in the hepatic 
uptake of fluvastatin. In addition, the Km for fluvastatin was calculated based on data 
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from only one experiment. The reliability of the results should be confirmed by future 
research. 
 
Fluvastatin is rapidly and completely metabolized after absorption primarily by 
CYP2C9 and to a lesser extent by CYP3A4, CYP2C8 and CYP2D6 in the liver, the 
elimination half-life (t1/2) being 0,7 to 0,8 hours (Dain et al. 1993; Scripture and Pieper 
2001). The main metabolites are two hydroxylated metabolites, 5-hydroxy-fluvastatin 
and 6-hydroxy-fluvastatin, and N-des-isopropyl-fluvastatin, which are excreted in the 
bile (Dain et al. 1993). Minor amounts of N-des-isopropyl-dihydro-fluvastatin tetranor, 
as well as glucuronide and sulfate conjugates of the main metabolites are also excreted 
in the urine. In the present study, the effect of rapid hepatic metabolism on the 
intracellular and extracellular concentration of fluvastatin in cryopreserved rat 
hepatocytes was investigated. The observed decrease in fluvastatin concentration in cell 
samples and in the sum of cell and supernatant samples indicates rather fast metabolism, 
which is in agreement with the human metabolism data. The maximum intracellular 
concentration decreased by 31 % in ten minutes. Such a high rate of metabolism has an 
effect on intracellular fluvastatin concentration already in 90 second incubation time 
used in the uptake experiments, which might lead to smaller perceived values of V and 
CLuptake.  
 
The presence of hydroxylated fluvastatin and fluvastatin glucuronide in cell and 
supernatant samples was confirmed in UPLC/MS analysis although the peak areas were 
very small compared to those of fluvastatin (Appendix 3). Direct comparison of 
metabolite and fluvastatin concentrations cannot be made using the peak areas. The lack 
of signal for major metabolite N-des-isopropyl-fluvastatin in the samples was surprising. 
It may be due to inter-species differences in fluvastatin metabolism or the used 
detection method of UPLC analysis. Quadrupole time-of-flight (QTOF) mass 
spectrometer would have enabled detection of metabolites with higher sensitivity and 
greater accuracy compared to of triple quadrupole MS (Zhang et al. 2000; Lacorte and 
Fernandez-Alba 2006).  
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8.3 Uptake Kinetics of Entacapone 
 
The lack of saturability in the uptake kinetics of entacapone indicates that hepatic 
uptake of entacapone is not predominantly mediated by active transport mechanisms in 
the concentration range of 3 – 160 µM. Entacapone is slightly lipophilic at pH 7,5, with 
an apparent octanol-water partition coefficient (logPapp) value of 0,8 (Forsberg et al. 
2005). The linear uptake kinetics is in agreement with lipophilicity, suggesting that 
entacapone is taken up into hepatocytes by passive diffusion. In a comparative 
experiment with passively permeating propranolol and Oatp inhibitor rifamycin, the net 
uptake and CLuptake of E3S in freshly isolated rat hepatocytes was almost identical when 
incubated with 50 µM entacapone or 50 µM propranolol, whereas incubation with 50 
µM rifamycin decreased the net uptake and CLuptake of E3S significantly. Entacapone 
did not seem to inhibit E3S uptake in low concentrations, the half maximal inhibitory 
concentration (IC50) being 237 µM. Altogether, entacapone did not seem to share same 
active transport mechanisms with E3S in rat hepatocytes to a significant degree. The 
results suggest that Oatp transporters do not play a major role in the hepatic uptake of 
entacapone in rats, although some inhibition of E3S uptake was observed at higher 
concentrations.  
 
However, the significant difference between the net uptake, V and CLuptake of 
entacapone between freshly isolated rat and cryopreserved human hepatocytes indicates 
that either hepatic uptake is inefficient due to lesser active uptake or more potent efflux 
or intracellular metabolism is much more rapid in human hepatocytes. Similar to 
fluvastatin, entacapone is rapidly metabolized in the human liver, t1/2 being only 0,4 - 
0,7 hours (Heikkinen et al. 2001). Species difference in biotransformation of entacapone 
between rats and humans has been reported but no published data about intrinsic 
clearance for metabolism in rats is available (Wikberg et al. 1993). Also the effect of 
cryopreservation on transporter function may contribute to the observed difference in 
intracellular drug concentration if active transport is responsible of entacapone uptake. 
If the species difference in intracellular entacapone concentration results from hepatic 
uptake rather than metabolism, the contribution of passive diffusion to the total hepatic 
uptake of entacapone may be smaller than the results from uptake experiments in rat 
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hepatocytes suggest. The significant carryover effect in the UPLC method of 
entacapone prevented the reliable quantification of low intracellular concentrations, 
which limited the data used in Km and IC50 calculations. Also more repetitions of the 
uptake assays would have been needed to improve the reliability of the results. The role 
of passive diffusion and active transport on hepatic uptake of entacapone should be 
further studied in the future using both 4 °C and 37 °C incubation conditions and more 
repetitions. 
 
8.4 Use of Non-Radiolabeled Compounds in the Oil-Spin Method 
 
Uptake experiments using the oil-spin method are usually performed using radio-
labeled compounds in order to enhance the rather low throughput of the method (Soars 
et al. 2009). In the present study, radiolabeled fluvastatin and entacapone were not 
available and intracellular concentrations of the drugs was determined using the oil-spin 
method adapted to non-radiolabeled compounds developed by Paine et al. (2008). 
Compared to experiments with radiolabeled compounds, quantification of samples with 
UPLC/MS analysis added more steps to the sample preparation process as lysed cells 
had to be extracted from the UPLC samples. Since cell samples had to be pipetted out of 
the original microcentrifuge tubes and precipitated in methanol, it is possible that part of 
the drug remained in the original tubes or in the lower ammonium acetate phase after 
methanol precipitation. It is also possible that cells in the reaction mixture samples were 
not properly lysed with the addition of methanol. This could be the reason why the 
quantified concentrations of reaction mixtures were lower than they were prepared to be. 
If the quantified concentrations did not reflect the actual concentrations of the reaction 
mixtures, the calculated CLuptake values for fluvastatin and entacapone should be lower.  
In addition to sample preparation, the finding of a good LC/MS method for 
quantification of samples can be problematic, as was seen for UPLC method of 
entacapone. Altogether, the oil-spin assay using non-radiolabeled substrates is a 
strenuous method that is clearly not useful in the early phases of drug discovery and 
development where higher throughput methods for screening of drug-transporter 
interactions are needed. 
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9 CONCLUSIONS 
 
In conclusion, by comparing the uptake kinetics of fluvastatin and entacapone on the 
uptake of taurocholic acid and estrone 3-sulfate in freshly isolated rat hepatocytes and 
cryopreserved rat and human hepatocytes, fluvastatin uptake showed active saturable 
transport kinetics with rapid metabolism in rat hepatocytes, whereas entacapone uptake 
in rat hepatocytes appeared to be linear and did not seem to inhibit active transport 
mechanisms of E3S at clinically significant concentrations. Significantly lower hepatic 
uptake of taurocholate and entacapone was observed between rat and human 
hepatocytes, although cryopreservation may have had an effect on the noticed difference. 
The overall results of the study suggest that Oatp transporters do not play a significant 
role in hepatic uptake of entacapone. However, the reliability of the results is 
questionable due to lack of parallel experiments and problems in the quantification of 
samples by UPLC/MS analysis. Further studies are needed to elucidate the role of active 
and passive processes in the hepatic uptake of entacapone. Knowledge about the 
substrates of Oatp transporters helps to assess drug disposition in humans and to explain 
drug interactions and interindividual variability in drug pharmacokinetics, efficacy and 
toxicity. 
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APPENDIX 1 
 
Summary of Nonlinear Regression Analysis of Taurocholate and Fluvastatin Uptake 
 
 
 
Taurocholate Fluvastatin 
Uptake CL    
Best-fit values 
 
 
     Vmax 1778 1171 
     Km 24,49 5,817 
     Pdiff 15,92 11,77 
Std. Error 
 
 
     Vmax 793,7 114,6 
     Km 39,60 2,006 
     Pdiff 446,5 57,84 
95% Confidence Intervals 
 
  
     Vmax 31,08 to 3525 907.3 to 1436 
     Km -62,68 to 111.7 1.191 to 10.44 
     Pdiff -966,9 to 998.7 -121.6 to 145.1 
Goodness of Fit 
 
 
Degrees of Freedom 11 8 
     R² 0,4365 0,9577 
Absolute Sum of Squares 4,939e+006 35812 
     Sy.x 670,1 66,91 
Constraints 
 
 
     Pdiff PPAS > 0.0 PPAS > 0.0 
     Km KM > 0.0 KM > 0.0 
 
  
  
APPENDIX 2 
 
Summary of Nonlinear Regression Analysis of E3S Inhibition by Rifamycin and 
Entacapone 
 
 
Rifamycin Entacapone 
Best-fit values 
       Bottom 1,00 x 10-07 1,00 x 10-07 
     Top 95,14 94,43 
     IC50 61,84 237,1 
Std. Error 
       Bottom 54,84 29,01 
     Top 5,336 4,776 
     IC50 83,06 160,9 
95% Confidence 
Intervals 
       Bottom 0,0 to 126,5 0,0 to 92,32 
     Top 82,84 to 189,7 79,24 to 138,5 
     IC50 0,0 to 253,4 0,0 to 749,1 
Goodness of Fit 
  
Degrees of Freedom 8 3 
     R² 0,8341 0,9594 
Absolute Sum of Squares 1263 116.3 
     Sy.x 12,57 6,227 
Constraints 
       BOTTOM BOTTOM > 0.0 BOTTOM > 0.0 
     TOP 
TOP > 
1,500*BOTTOM 
TOP > 
1,500*BOTTOM 
     IC50 IC50 > 0.0 IC50 > 0.0 
 
  
  
APPENDIX 3 
 
Peak Areas of Fluvastatin and its Metabolites in UPLC/MS Analysis 
 
 Analyte peak area 
Time (s) Fluvastatin OH-fluvastatin Fluvastatin 
glucuronide 
 Cells Supernatant Cells Supernatant Cells Supernatant 
30 292000  1283333 0,0 16,3 2,8 2170 
90 341333 1236667 0,9 27,9 2,8 1533 
180 391667 1143333 1,4 1079 3,4 1923 
300 420667 1053333 1066 2587 3,9 1890 
600 307333 969333 9,8 7733 5,6 1653 
900 300333 925667 1513 12400 3,5 1833 
 
